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 RUNX3 (Runt-related transcription factor 3) is a well-documented tumour 
suppressor, whose inactivation, either due to promoter methylation or protein 
mislocalization, is frequently observed in gastric cancer. The mechanisms by 
which RUNX3 exerts its tumour suppressor activities are not fully understood 
yet. TEAD-YAP complex is a transcriptional factor regulating cell proliferation 
and migration. In normal quiescent adult cells, the activity of TEAD-YAP 
complex is restricted at a low level by Hippo pathway as well as other 
mechanisms, while the hyper-activation of TEAD-YAP complex is frequently 
observed in liver cancer and breast cancer.  
 In this study, we proved that the TEAD-YAP complex also conferred strong 
oncogenic activities in gastric epithelial cells. The higher expression of TEAD-
YAP in tumour tissues significantly correlated with poorer overall survival time 
in a gastric cancer cohort. Strikingly, RUNX3 physically interacted TEAD 
(TEA domain family members) proteins through its Runt domain. This 
interaction markedly reduced the DNA binding ability of TEAD, which 
attenuated the downstream signalling of TEAD-YAP complex.  
 Our findings identify RUNX3 as a novel negative regulator of TEAD-YAP 
complex. Our discoveries also reveal that a significant aspect of RUNX3’s 
tumour suppressor function is via its negative regulation of TEAD-YAP 
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Introduction 
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1.1 A brief introduction about gastric cancer 
 Cancer is the leading cause of death in developed countries and the second 
leading cause of death in developing countries (Ferlay et al, 2010). Among all 
kinds of cancers worldwide, gastric cancer ranks fourth in incidence (after lung, 
breast and colorectal) and second in mortality (after lung cancer) (Jemal et al, 
2011). Eastern Asia has the highest incidence of gastric cancer, reflecting the 
role of dietary patterns and prevalence of Helicobacter pylori (H.pylori) 
infection in the progression of disease (Parkin, 2006).  
 According to Laurén classification system, histologically there are two 
major types of gastric cancer: (1) intestinal type gastric cancer, which is 
characterized by malignant epithelial cells that show cohesiveness and 
glandular differentiation infiltrating the stroma; (2) diffuse type gastric cancer, 
which is composed of discohesive cells that infiltrate the stroma individually or 
in small groups. A small percentage of gastric adenocarcinomas are mixed, 
presenting features of both types (Lauren, 1965).  
 Gastric cancer is a multifactorial disease caused by a variety of infectious, 
environmental, and host-related factors.  A small percentage of gastric cancer 
can be attributed to familial cancer syndromes, including hereditary diffuse 
gastric cancer, which is caused by mutations of CDH1 gene (encoding a cell 
adhesion protein E-cadherin), and Lynch syndrome, which is caused by 
mutations of MLH1, MSH2, MSH6, PMS2, or EPCAM  (encoding proteins 
involved in DNA repair) (Caldas et al, 1999).  
 However, most gastric cancer cases are sporadic and influenced by 
infectious factors and environmental factors. H.pylori infection has been 
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recognized as a type I carcinogen by International Agency for Research on 
Cancer since 1994, due to its strong correlation with gastric cancer (Vogiatzi et 
al, 2007). Environmental and lifestyle factors including tobacco smoking, high 
salt intake and meat consumption, increase the risk of developing gastric cancer, 
while an adequate intake of fresh fruits and vegetables decreases risk of gastric 
cancer (Gonzalez & Agudo, 2012).  
 Currently, some genome-wide association studies (GWAS) have been 
conducted to identify more genetic factors related to sporadic gastric cancer. 
Single Nucleotide Polymorphism (SNP) of Prostate stem cell antigen (PSCA) 
gene and Mucin 1 (MUC1) gene show positive correlation with diffuse type 
gastric cancer (Saeki et al, 2013; Study Group of Millennium Genome Project 
for et al, 2008). A recent exome sequencing project using gastric cancer 
specimen identified TP53, PIK3CA, ARID1A as well as FAT4 as frequently 
mutated genes (Zang et al, 2012). More in-depth research is needed to reveal 
the underlying relationship between mutated genes and gastric cancer. 
  The focus of this thesis, RUNX3 and TEAD-YAP complex, are both 
closely related to the progression of gastric cancer, either as a tumour 
suppressor or an oncogene. The biological functions and importance of them 
would be further explained in following chapters. 
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1.2 A brief introduction of Runt-Related Transcription Factor family 
1.2.1 Runt-Related Transcription Factor family (RUNX family) 
Runt (Drosophila homolog of RUNX genes) was first discovered as one of 
the genes required for the establishment of segmented body pattern of the 
Drosophila embryo (Gergen & Butler, 1988). The pattern of runt transcript 
accumulation undergoes a series of changes during the early stages of 
Drosophila embryogenesis, suggesting its critical role in development.  
Later, RUNX1 gene (named as AML1 at the time of discovery) was 
identified as a part of the fusion gene generated by t(8;21) chromosome 
translocation frequently observed in acute myeloid leukemia (AML), indicating 
that RUNX1 is involved in the neoplasitc transformation of AML carrying this 
translocation (Miyoshi et al, 1991). Further studies have proven the correctness 
of this hypothesis, which would be explained in details in Chapter 1.2.2. 
During the studies of polyomavirus in mouse embryonic cells, many 
observations were obtained showing the existence of pylyomavirus enhancer 
binding protein, which bound to the polyomavirus enhancer (Kryszke et al, 1987; 
Piette & Yaniv, 1987). Further analysis showed that pylyomavirus enhancer 
binding protein consisted of two subunits: α subunit, which bound to DNA, and 
β subunit, which enhanced the DNA binding ability of α subunit. Later, RUNX2 
was isolated as α subunit of pylyomavirus enhancer binding protein 2 (PEBP2; 
also called PEA2) (Ogawa et al, 1993b). The sequence and function of β subunit 
of PEBP2 (now known as CBFβ) were also described during this period (Ogawa 
et al, 1993a; Wang et al, 1993). Shortly after RUNX2’s discovery, the third 
member of RUNX family, RUNX3 gene, was cloned by independent groups 
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(Bae et al, 1995; Levanon et al, 1994). Even since then, a new voyage had begun, 
searching for a better understanding about the structure as well as functions of 
RUNX proteins. 
RUNX proteins are highly evolutionarily conserved from unicellular 
Capsaspora owczarzaki to mammals, indicating these proteins’ importance in 
metazoan as well as their single-celled ancestors (Sebe-Pedros et al, 2011). 
There are three mammalian runt-related genes: RUNX1, RUNX2 and RUNX3, 
which play distinct roles during normal development or diseases.  
The RUNX family members show a high degree of structural and sequence 
homology within the Runt domain and VWRPY domain at the C-terminal end. 
The diagrammatic representation of these domains is shown in Figure 1.1A, and 
the comparison of amino acid sequences of RUNX proteins across various 
species is shown in Figure 1.1B. Such a high level of conservation reflects the 
importance of these domains for the proper function of RUNX family. 
- 6 - 
 
Figure 1.1 Runt domain and VWRPY domains are highly conserved in Runt-
Related Transcription Factor family. (A) A diagrammatic representation of 
RUNX1, RUNX2 and RUNX3 together with Drosophila Runt. Conserved Runt 
domain (red) and VWRPY sequence (black) at the C-terminus of the proteins 
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are indicated. (B) Comparison of amino-acid sequences of the RUNX proteins 
of various species. The gray bars below sequences indicated the level of 
conservation of each amino acid residue. The Runt domain and VWRPY are 
highly conserved among species. (Ito, 2004) 
 
 
The Runt domain confers sequence-specific DNA binding and dimerization 
with non DNA-binding partner, core-binding factor β (CBFβ), which can 
enhance the DNA binding affinity, compared with Runt domain alone (Kamachi 
et al, 1990). The three-dimensional crystal structure of the Runt domain, 
heterodimerized with the 134-amino acid region of CBFβ and bound to DNA, is 
shown in Figure 1.2. The consensus sequence for DNA binding of RUNX 
family is either 5’-ACCpuCA-3’ or in the reverse orientation, 5’-TG(T/C)GGT-
3’. However, the sequence 5’-ACCACA-3’ appears more frequently in RUNX 
target promoters than other sequences which are also in agreement with the 
consensus (Otto et al, 2003). Figure 1.3 summarizes all possible RUNX binding 
sites (Ito, 2008). Heterodimerization of CBFβ with RUNX proteins can also 
prevent the ubiquitination and degradation of RUNX proteins. Due to CBFβ’s 
essential functions, Cbfβ knockout mice manifest a phenotype which is very 
similar to that of Runx deficiency, showing a failure of definitive hemopoiesis, 
at a very early age of embryogenesis (Wang et al, 1996). 
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Figure 1.2 Crystal structure of the Runt domain heterdimerized with CBFβ 
bound to DNA. (Ito, 2004) 
 
Figure 1.3 Preferred RUNX binding sequences. (Ito, 2008)  
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The VWRPY motif, which is located at the carboxyl-terminal end, 
modulates RUNX proteins’ transcriptional activity by recruiting transducin-like 
enhancer (TLE)/Groucho co-repressor (Aronson et al, 1997). This interaction is 
crucial for the epigenetic silencing of CD4 by RUNX3 in CD8
+
 T cells, and 
Runx3
VWRPY−/−
 mice also exhibit failure in retaining spontaneous maturation of 
dendritic cells (Yarmus et al, 2006). 
RUNX proteins are context-dependent transcription regulators, which can 
either activate or repress gene expression by cooperating with specific 
transcription factors or cofactors in specific tissue types (Wheeler et al, 2000). 
RUNX1’s opposite roles on p21Waf1/Cip1 promoter in different conditions serves 
as a typical example to illustrate this point. Specifically, RUNX1 can interact 
with Sin3A co-repressor at residues 208–237, repressing p21Waf1/Cip1 promoter in 
NIH3T3 cells (Lutterbach et al, 2000). Meanwhile, RUNX1 is also able to form 
a complex with p53 upon adriamycin (ADR) exposure, and stimulates the 
transcription of p53 target genes such as p21
Waf1/Cip1
, BAX, NOXA, and PUMA in 
HCT116 and U2OS cells (Wu et al, 2013).  
RUNX proteins function as transcriptional activators in multiple ways. For 
example, RUNX1 can cooperate with Myb, C/EBPα, P300/CBP and P/CAF, 
forming a multimeric complex and activating MPO (Myeloperoxidase) gene 
expression though the recruitment of the basal transcription factors and 
chromatin acetylation during myeloid cell differentiation (Kitabayashi et al, 
1998). Moreover, RUNX1 and Ets-1 can mutually stimulate each other’s DNA 
binding activity and transactivation function by masking the autoinhibitory 
domain of each other through protein-protein interaction, and cooperate 
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synergically for the transactivation of the T cell receptor (TCR) beta chain 
enhancer (Kim et al, 1999b). 
On the other hand, RUNX proteins also function as transcriptional 





mice in which the VWRPY motifs are removed from both the Runx1 and Runx3 
proteins, Full CD4 de-repression of mature CD8
+
 T cells is observed, while 
ThPOK (T-Helper-Inducing POZ/Krueppel-Like Factor) is only partially de-
repressed, indicating that RUNX proteins suppress CD4 expression in a 
VWRPY dependent manner, while they suppress ThPOK expression in both 
VWRPY dependent and independent manners (Seo et al, 2012). Till now, 
several VWRPY independent mechanisms of gene repression have been 
discovered. Firstly, RUNX1 can recruit Sin3A co-repressor to repress 
p21
Waf1/Cip1
 promoter in NIH3T3 cells (Lutterbach et al, 2000). Secondly, 
RUNX1 and RUNX3 can associate with SUV39H1, a histone methyltransferase 
involved in gene silencing (Durst & Hiebert, 2004).  
Since RUNX proteins have complicated roles as versatile gene expression 
regulators in the determination of cell fate during development, their 
deregulation often leads to serious disease like cancer (Blyth et al, 2005). Table 
1.1 is a summary about each RUNX protein’s essential functions, knockout 
mice’s phenotype and roles in tumorigenesis, which would be further explained 
in later chapters.  
  















Hemizygocity in humans 
predisposes to Familial platelet 
disorder with predisposition to 
acute myelogenous leukemia 
(FPD/AML).  
Frequent target of chromosome 
translocation and mutations in acute 
myeloid leukemia. 





Dies at birth 
from respiratory 
failure. 
Transgenic Runx2 overexpression 
predisposes to T-cell lymphomas.  
Elevated expression in 
osteosarcoma tumours. 
Expressed by metastatic cancer 
cells to promote their homing to the 
bone. 






























Frequently inactivated in human 
gastric cancer, colon cancer, lung 
cancer and breast cancer by 
promoter methylation, Loss of 
heterozygosity or mis-localization. 
Possess an oncogenic role in 




Table 1.1 Functions, knockout mice’s phenotype and roles in oncogenesis of 
Runt-related transcription factors.  [Modified from (Lund & van Lohuizen, 
2002)].  
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1.2.2 RUNX1 and RUNX3’s roles in hematopoiesis and leukemia 
As indicated in Table 1.1, both RUNX1 and RUNX3 play a role in cell 
differentiation during hematopoiesis, which would be further explained in this 
section. 
RUNX1 is the master regulator of definitive hematopoiesis in mammals 
(Okuda et al, 1996). Homozygous deletion of Runx1 would result in a complete 
lack of definitive hematopoiesis, indicating that RUNX1 is indispensable for 
definitive hematopoiesis (Okuda et al, 1996; Wang et al, 1996). Further research 
suggested that RUNX1 is critical for the emergence of the first hematopoietic 
stem cells (HSCs) from hemogenic endothelium in the embryonic aorta-gonad-
mesonephros (AGM) region (North et al, 1999; Yokomizo et al, 2001). 
Conditional knockout of Runx1 in adult mice would lead to hematopoietic stem 
cell exhaustion after an initial short term expansion of HSCs with limited self-
renewal capacity, possibly due to the compromised HSC-niche interactions 
(Ichikawa et al, 2004; Jacob et al, 2010). HSC with long term self-renewal 
capacity would exit quiescence in responding to disrupted HSC-niche 
associations, and become short term HSCs, causing the stem cell exhaustion 
(Wang et al, 2010).  These observations show the importance of RUNX1 for 
maintaining HSCs in quiescence through a niche-related mechanism, whose 
deficiency triggers a pre-leukemic state by increasing the number of short term 
HSCs as a cell pool for further oncogenic alterations (Growney et al, 2005; Putz 
et al, 2006). 
Apart from its role in hematopoietic stem cells, RUNX1 is also essential for 
the differentiation of T and B cells in adult hematopoiesis (Ichikawa et al, 2004). 
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RUNX3 is also involved in this process, playing both redundant and non-
redundant roles with RUNX1. During the development of T lymphocytes, First, 




 double negative 
immature thymocytes through direct binding to two RUNX-binding motifs in 





RUNX3 also suppresses CD4 expression in a similar manner (Grueter et al, 
2005). During the development of B cells, Runx1 is essential at two stages: (1) 
to promote survival and development of progenitors specified to the B-cell 
lineage; (2) to enable the developmental transition through the pre-B stage 
triggered by the pre-B-cell antigen receptor (pre-BCR) (Niebuhr et al, 2013). 
RUNX3 has a role in B-cell development at a later stage than RUNX1 (de 
Bruijn & Speck, 2004). RUNX3 mediates TGFβ activation of the germline Igα 
promoter in advance of IgA class switching in cooperation with the Smad family 
of transcription factors (Shi & Stavnezer, 1998). Furthermore, in naive B cells, 
RUNX3 suppresses the expression of RUNX1 after activation or Epstein–Barr 
virus (EBV) infection (Spender et al, 2005), by binding specifically to conserved 
RUNX binding sites in RUNX1’s P1 promoter in a VWRPY dependent manner 
(Brady et al, 2009).  
Apparently, RUNX1 is involved in multiple levels of adult hematopoiesis 
from the maintenance of quiescent HSCs to defining proper differentiation 
programs towards a full range of hematopoietic lineages. Given such pivotal 
roles in mammalian hematopoiesis, it is not surprising to note that RUNX1 is 
one of the most frequently disrupted genes in human leukemias (Look, 1997). 
Loss of RUNX1’s function due to chromosomal translocations or point 
mutations is common in various types of leukemias such as acute myelogenous 
- 14 - 
 
leukemia, myelodysplastic syndrome, chronic myelogenous leukemia and 
childhood acute lymphoblastic leukemia (Golub et al, 1995; Mitani et al, 1994; 
Nucifora et al, 1993).  
RUNX1-ETO caused by t(8;21) translocation fuses the DNA-binding 
domain of RUNX1 to the transcriptional co-repressor ETO protein (Gao et al, 
1991). It is one of the most common molecular abnormalities in acute 
myelogenous leukaemia (AML), with a frequency of approximately 12%  
(Peterson & Zhang, 2004). AML1-ETO negatively regulates AML1 target genes 
including IL-3, c-fos, TCRβ, immunoglobulin α, and p14ARF (Frank et al, 1995; 
Linggi et al, 2002; Meyers et al, 1995). RUNX1-ETO can also activate the 
expression of genes including M-CSF receptor, BCL2 and G-CSF receptor 
(Klampfer et al, 1996; Petrovick et al, 1998; Shimizu et al, 2000). The effects of 
this fusion protein are highly context-dependent, depending on the RUNX1 
DNA binding site in the regulatory element of its target gene or the presence of 
other transcription regulators interacting with it (Peterson & Zhang, 2004). 
However, this t(8;21) translocation is a leukemia-initiating event, and fusion 
gene sequences can be found long before the onset of leukaemia in the blood 
from newborn children (Wiemels et al, 2002). The requirement of secondary 
genetic alterations for the full induction of developed AML in t(8;21) patients 
reflects the complexity of pathogenic mechanisms of AML (Yuan et al, 2001). 
Another fusion protein TEL-RUNX1 (also known as ETV6-RUNX1) is 
observed in 20% of pediatric B-cell acute lymphoblastic leukaemia’s (ALL). It 
is caused by t(12;21) translocation, juxtaposing the RUNX1 gene on 
chromosome 21 with the TEL/ETV6 gene on chromosome 12 (Shurtleff et al, 
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1995). TEL-AML1 increases the self-renewal capacity of myeloid progenitors 
and impairs differentiation of the B-cell compartment, resulting in the 
accumulation of both multipotent and B-cell progenitors (Fischer et al, 2005). 
TEL-RUNX1 fusion protein represses RUNX1 targets like Complement 
Component (3b/4b) Receptor 1 (CR1) as well as genes which are not usually 
regulated by RUNX1 (Kim et al, 1999a). Several mechanisms have been 
proposed, including the recruitment of nuclear hormone co-repressor (N-Cor) 
and histone deacetylase (mSin3A), heterodimerization with TEL or sequestering 
p300 into the cytoplasm (Lee et al, 2004). By multiple means, TEL-RUNX1 
interferes with RUNX1’s key regulatory functions and globally re-shapes the 
biological process of lymphocytes (Fischer et al, 2005). 
Taken together, RUNX1 is a key regulator of both embryonic and adult 
hematopoiesis where its disruption is strongly linked to leukemogenesis, while 
RUNX3 also plays a part in the cell lineage decisions in thymopoiesis. 
 
1.2.3 RUNX2 in skeleton development and cancer metastasis 
RUNX2 plays critical functions for the bone formation in mammals (Chen 
et al, 2012). Runx2
-/-
 mice show impaired osteoblasts maturation and 
osteogenesis, causing a complete lack of bone formation, so these mice would 
die soon after birth due to severe respiratory defects possibly caused by the 
absence of a proper rib cage (Komori et al, 1997; Otto et al, 1997). 
RUNX2 regulates the expression of some bone-specific genes such as 
osteocalcin and alkaline phosphatise during osteoblast differentiation from 
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mesenchymal precursor cells (Ducy et al, 1999). Runx2
+/-
 mice display skeletal 
abnormalities resembling that of the human congenital skeletal disorder called 
cleidocranial dysplasia, and mutations of RUNX2 have been identified in 
patients suffering from this disease (Tessa et al, 2003; Xuan et al, 2008).  
RUNX2 is also able to promote the metastasis and bone-homing of tumour 
cells in breast and prostate tumours (Akech et al, 2010; Das et al, 2009; Javed et 
al, 2005; Lim et al, 2010; Pratap et al, 2008). RUNX2 can induce epithelial-
mesenchymal transition (EMT) by sitimulating SNAI2 expression in a Wnt and 
transforming growth factor β (TGFβ) dependent manner (Chimge et al, 2011). 
Reduction of RUNX2 by RNAi in MDA-MB-231 breast cancer cell line 
significantly reduces cell motility, with only marginal effects on cell growth 
(Leong et al, 2010). A transcriptome profiling in prostate cancer cells with 
induced RUNX2 expression showed that RUNX2 up-regulated the expression of 
SDF-1 (The stromal cell-derived factor 1), CXCR7 (C-X-C chemokine receptor 
type 7) and BSP (Bone sialoprotein), which promoted homing and attachment to 
bone (Baniwal et al, 2010). At the same time, RUNX2 up-regulated osteoclast 
activators like CSF2 (Colony Stimulating Factor 2) and SPHK1 (Sphingosine 
Kinase 1), to alter the bone microenvironment in response to prostate cancer 
metastasis to further fuel the growth tumour cells (Baniwal et al, 2010).  
Our increasing knowledge about RUNX2’s role in bone formation as well 
as cancer metastasis reflects the versatility of RUNX proteins in various 
biological processes. 
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1.2.4 RUNX3’ role in the development of dorsal root ganglion neurons 
RUNX3 is highly expressed in the dorsal root ganglion neurons (DRG), 
spleen and thymus. Its expression is relatively lower in epithelia in various 
organs likes lung, liver and gastrointestinal tract (Inoue et al, 2007; Ito et al, 
2009; Ito et al, 2008; Levanon et al, 2002; Li et al, 2002; Taniuchi et al, 2002; 
Woolf et al, 2003).  
In the developing DRGs of mice embryo, Runx3 is first detected at E10.5 in 
numerous neurons, and it is co-expressed with the proprioceptive markers 
including tyrosine kinase receptor C (TrKC) and parvalbumin (PV). Runx3-
deficient mice develop severe limb ataxia and abnormal posture. Different views 
still exist about the cause of this phenotype. Inoue, et al showed that Runx3−
/− 
mice maintained normal number of TrkC positive DRG proprioceptive neurons 
throughout development, but these DRG neurons failed to form target-specific 
axon pathfinding in the spinal cord (Inoue et al, 2003). However, Levanon, et al 
suggested that the number of DRG proprioceptive neurons decreased and they 
could not survive long enough to extend their axons toward target cells in the 
absence of Runx3, resulting in a lack of connectivity and ataxia (Levanon et al, 
2002).  
Apart from the different opinions about RUNX3’s role in the survival of 
DRG proprioceptive neurons, a common conclusion is that RUNX3 has a 
critical role in the proper development of dorsal root ganglion neurons. 
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1.2.5 RUNX3’s role in cancer development 
Except in the embryonic dorsal root ganglion neurons, RUNX3’s 
expression in other epithelia is generally lower than that in spleen and thymus. 




 mice displayed hyperplasia of epithelium in gastrointestinal tract, 
mammary glands and lung. Further analysis performed in newborn mouse 
stomach revealed that the glandular stomach displayed excessive cell 
proliferation and inhibition of apoptosis induced by TGF-β in the epithelial cells, 
suggesting the importance of Runx3 in the TGF- β signalling (Li et al, 2002). A 
small number of these mice can survive to adulthood, and these mice exhibit a 
significant elevation of Trefoil Factor 2 (TFF2) level in mucin 6 (Muc6)-
expressing cells, coupled with a lack of chief cells, presenting a remarkably 
similar phenotype to SPEM (Spasmolytic polypeptide-expressing metaplasia), a 
precancerous state of the stomach. At the same time, the Runx3
-/-
 gastric 
epithelium exhibits an intestinal phenotype, marked by the expression of 
intestine-specific transcription factor Cdx2, whose expression is triggered by β-
catenin/TCF, which is hyperactivated due to loss of Runx3 (Ito et al, 2011). 
About 20% of Runx3
+/− 
female mice develop mammary tumours at the age 
of 15 months. The expression of estrogen receptor α (ERα) is significantly 
enhanced in these tumours. Further studies revealed that RUNX3 could 
vigorously reduce the transcriptional activity of ERα by inducing the 
proteasome-mediated degradation of ERα (Huang et al, 2012). This mechanism 
suggests that RUNX3 functions as a “gate-keeper” to prevent the onset of breast 
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cancer by controlling the mammary epithelial cells’ response to circulating 
estrogens through restricting the cellular level of ERα (Chen, 2012). 
Runx3
-/-
 mouse embryos begin to develop lung hyperplasia at E17.5. The 
proliferation marker Ki67 is more abundant in the Runx3
-/-
 lungs (84%) than in 
wild-type lungs (53%), possibly because Bim expression is reduced when 
Runx3 is deficient. 85% of Runx3
+/-
 mice develop spontaneous lung adenomas 
at 18 months of age, while only 3% develop lung adenocarcinomas (Lee et al, 
2010). K-Ras mutation might be associated with the progression from adenoma 
to malignant carcinoma. In another study using targeted inactivation of Runx3 in 
mouse lung, oncogenic K-Ras can markedly shorten the latency of 
adenocarcinoma formation caused by loss of Runx3, due to the impairment of 
oncogenic K-Ras induced p14
ARF
-p53 pathway when Runx3 is knocked out (Lee 
et al, 2013). 
The tumour suppressor activities of Runx3 observed during the analysis of 
Runx3
 
knockout mice are further supported by human clinical data. In human, 
silencing of RUNX3 is observed in about 80% of primary gastric cancer 
specimen as well as gastric cancer cell lines, due to promoter hypermethylation, 
hemizygous deletions or protein mislocalization into cytoplasm (Ito et al, 2008; 
Ito et al, 2005). Down-regulation of RUNX3 could be frequently observed even 
from the precancerous intestinal metaplasia (IM) in stomach, which would 
provide favourable conditions for the progression from adenomas to malignant 
adenocarcinomas (Li et al, 2002).  
Loss of RUNX3 function is observed in nearly all human breast cancer 
samples, due to promoter hypermethylation and mislocalization (Lau et al, 2006; 
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Subramaniam et al, 2009). This event takes place from the ductal carcinoma in 
situ (DCIS) stage, supporting the theory that RUNX3 functions as a “gate-
keeper” to prevent the onset of breast cancer by controlling the mammary 
epithelial cells’ response to circulating estrogens through restricting the cellular 
level of ERα (Chen, 2012). 
In human lung cancer, inactivation of RUNX3 is observed in 70% of the 
adenocarcinoma (ADC) samples, while the frequency is only 20% in squamous 
cell carcinoma (SCC) samples, indicating that RUNX3 might have different 
roles in ADC and SCC (Omar et al, 2012). 
Taken together, data from both mice and human strongly argue that 
RUNX3, whose disruption appears to be a key event in early gastrointestinal 
carcinogenesis, breast cancer and lung cancer, functions as a tumour suppressor 
in various kinds of solid tumours. But there are still some exceptions. RUNX3 
exhibits oncogenic activity in ovarian cancer as well as head and neck cancer, 
whose mechanism is not thoroughly understood yet (Kudo et al, 2011; Lee et al, 
2011a).  
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1.3 RUNX3’s involvement in major signalling pathways 
 As it is shown in Chapter 1.2.5, conclusive evidence generated in clinical 
specimen as well as mouse model shows that RUNX3 functions as a tumour 
suppressor in various kinds of cancers. Till now, an enormous amount of 
research effort has been devoted into the study about the mechanisms how 
RUNX3 achieves such an important function. 
 Great progress has been made in understanding RUNX3’s versatile roles in 
several major signalling pathways, including TGF-β/SMAD signalling pathway, 
Wnt pathway way, K-RAS-p14
ARF
-p53 pathway, which would be further 
explained in details in this chapter.  
1.3.1 RUNX3 in the TGF-β/SMAD signalling pathway 
Transforming growth factor-β (TGF-β) is a family of multifunctional 
cytokines that regulate cell growth, differentiation, apoptosis, matrix 
accumulation and motility (Blobe et al, 2000; Derynck & Feng, 1997; Massague, 
2012). It is a potent cell growth inhibitor for hematopoietic cells, endothelial 
cells and epithelial cells, while it stimulates the growth of mesenchymal cell 
(Derynck et al, 2001). TGF-β superfamily mainly consists of TGF-βs, activins 
and bone morphogenetic proteins (BMPs). Binding of these TGF-β ligands 
causes the formation of type I or type II receptor heterodimeric complex, leading 
to the activation of downstream effectors of the SMAD family. SMAD2 and 
SMAD3 belong to R-SMADs transducing the TGF-β/activin-like signals while 
SMAD1, SMAD5 and SMAD8 belong to R-SMADs mediating BMP-like 
signals (Miyazono et al, 2004). These receptor-activated SMADs (R-SMADs) 
get phosphorylated and associate with SMAD4 (Co-SMAD) and translocate to 
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cell nucleus to regulate the transcription of target genes together with other 
transcription factors (Feng & Derynck, 2005; Massague et al, 2005).  
TGF-β family members have both tumour suppressive and oncogenic 
activities (Massague, 2012). According to the current paradigm, the tumour 
suppressive functions of TGF-β dominate in normal tissues or in early stages of 
cancer. However, as the cancer advances, changes of TGF-β expression or 
cellular responses tip the balance in favour of its oncogenic activities, which is 
supported by the observation that activated TGF-β signalling promotes cancer 
progression and metastasis via epithelial-mesenchymal transition (EMT), 
angiogenesis and immune-suppression (Derynck et al, 2001; Wakefield & 
Roberts, 2002). 
All three RUNX proteins have been shown to physically interact with R-
SMADs (Hanai et al, 1999). As we have mentioned in chapter 1.2.2, RUNX3 
plays an important role in B cell maturation by interacting with SMAD2 and 
SMAD3 to cooperatively activate germline immunoglobulin constant α (IgCα) 
promoter to direct class switching to IgA in B lymphocytes (Hanai et al, 1999; 
Pardali et al, 2000). In the gastrointestinal tract, where TGF-β pathway mainly 
functions as a tumour suppressor pathway, RUNX3 cooperates with R-SMADs 
to activate the transcription of the negative regulators of cell cycle, p21
WAF/Cip1
 
and proapopototic gene, BIM (Chi et al, 2005; Ito, 2008; Mishra et al, 2005; 




 GIF cells are highly 
resistant to TGF-β1 induced growth arrest and apoptosis and they also exhibit 
spontaneous epithelial-mesenchymal transition (EMT) due to dysregulation of 
the TGF-β pathway (Li et al, 2002; Voon et al, 2012). In the skeletal system, 
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where RUNX2 is the dominant RUNX protein, impaired RUNX2-SMAD 
interaction due to RUNX2 mutation may contribute the cleidocranial dysplasia, 
since the physical interaction between RUNX2 and BMP-specific SMAD1 or 
SMAD5 synergistically activates osteoblast-specific gene expression in 
pluripotent mesenchymal precursor cells (Zhang et al, 2000). 
Based on these evidences, RUNX proteins can form complexes with 
specific R-SMADs to control transcription in a context dependent manner, 
functioning as nuclear effectors of TGF-β signalling pathway. Modulation of the 
TGF-β pathway partially contributes to the tumour suppressor functions of 
RUNX3.  
 
1.3.2 RUNX3 attenuates the oncogenic Wnt signalling pathway 
The canonical Wnt pathway is critical for cell fate determination during 
embryogenesis and it orchestrates self-renewal in various tissues (Clevers, 2006). 
Wnt signalling would functionally deactivate glycogen synthase kinase-β 
(GSK3β) and promote the stabilisation of cytoplasmic β-catenin, resulting in the 
translocating of unphosphorylated β-catenin into cell nucleus to stimulate the 
transcription of Wnt target genes by interacting with T-cell factor (TCF) or 
lymphoid enhancer-binding factor (LEF) (Bienz & Clevers, 2000). In Tcf-4
-/-
 
mice, the proliferative stem cell compartment is entirely absent in small 
intestines, suggesting that Wnt/TCF4/β-catenin pathway is necessary for the 
maintenance of crypt stem/progenitor cells in intestinal epithelium (Korinek et 
al, 1998). Further study revealed that Wnt target gene, leucine-rich repeat-
containing G-protein coupled receptor 5 (Lgr5) could mark the crypt base 
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columnar (CBC) cells, which could give rise to all lineages of intestinal 
epithelium and maintain the epithelia self-renewal over a long period of time 
(Barker et al, 2007).  
The dysregulation of Wnt signalling is closely correlated with 
gastrointestinal cancers (Clevers, 2006). Inactivation of adenomatous polyposis 
coli (APC) complex or oncogenic mutations of β-catenin would lead to aberrant 
stabilisation and nuclear accumulation of β-catenin, finally causing cancer 
(Bienz & Clevers, 2000; Kinzler & Vogelstein, 1996). For example, in Apc
min/+
 
transgenic mice, which carry a heterozygous mutation of Apc tumour suppressor 
gene, spontaneous intestinal adenomas are repeatedly observed (Moser et al, 
1990).  
RUNX3 is able to antagonize Wnt signalling through a direct interaction 
with TCF4/β-catenin complex. This ternary complex has a significantly 
impaired DNA binding ability, resulting in a reduction of TCF4/β-catenin’s 
transcriptional activity. Supportive to this mechanism, target genes of β-
catenin/Tcf4, like CD44, cyclin D1, c-Myc, conduction and EphB2, are all up-
regulated in intestinal epithelial cells of Runx3
−/−
mice, in which small adenomas 
develop at a frequency comparable to that of Apc
Min/+ 
mice in small intestine at 
around 65 weeks of age. In human colorectal cancer specimen, inactivation of 
RUNX3, either by loss of expression or mislocalization, is frequently 
concomitant with accumulation of β-Catenin, which would lead to ligand-
independent and unconstrained Wnt pathway signalling that favours the 
progression of tumours (Ito et al, 2008). 
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Similar observations can be obtained in stomach. β-catenin/TCFs’ 
occupancy on Cdx2 promoter and c-Myc promoter is significantly higher in 
gastric epithelial cells when Runx3 is knocked out, causing an intestinal 
phenotype as well as an increased proliferation capacity in Runx3
-/-
 gastric 
epithelium. R122C mutation within the Runt domain of RUNX3 is previously 
identified in a gastric cancer patient (Li et al, 2002). This RUNX3R122C mutant, 
which exhibits weaker binding with β-catenin/TCF than wild-type RUNX3, can 
not effectively reduce Cdx2 and c-Myc expression, indicating that hyper-
activated Wnt signalling, due to mutation of RUNX3, might contribute to the 
progression of tumour for this patient (Ito et al, 2011).  
The research performed in both intestine as well as stomach highlights the 
importance of RUNX3 as a negative regulator for oncogenic Wnt pathway, 
which partially explains the strong tumour suppressor activity of RUNX3 we 
observed in clinical specimen as well as in mouse models. 
 
1.3.3 RUNX3 mediates K-Ras
G12D
 dependent ARF-p53 activation 
p53 is the tumor suppressor which is most frequently mutated in human 
cancers (Hollstein et al, 1991). Wild-type p53 functions as a tetrameric 
transcription factor that regulates cell growth, inhibiting the cell cycle in some 
circumstances and promoting apoptosis in others, through the activation or 
repression of key target genes, such as CDKN1A, CDC25C and BAX (Lohr et al, 
2003; Miyashita & Reed, 1995; Riley et al, 2008; St Clair et al, 2004). It has 
also been suggested that p53 promotes apoptosis and inhibits autophagy in the 
cytoplasm through mechanisms that do not involve transcription (Green & 
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Kroemer, 2009). Generally speaking, p53 is highly versatile, functioning in 
various cellular process including senescence, metabolism, autophagy, 
angiogenesis and DNA repair, and this explains why p53 is frequently mutated 
in human cancer (Dameron et al, 1994; Nigro et al, 1989; Serrano et al, 1997; 
Smith et al, 1995; Tasdemir et al, 2008; Vousden & Ryan, 2009).  
It is a common observation that excessive expression of genes that normally 
induce mitogenic signals, such as MYC or RAS, can activate p14
ARF
, which 
stabilizes p53 (Palmero et al, 1998). The stabilized p53 would trigger the 
expression of p21
WAF/CIP
 and proapoptotic genes, resulting in cell cycle arrest, 
premature senescence and apoptosis. This process is sometimes referred as 
ARF-p53-p21 pathway, which is an important cell defense against oncogenic 
transformation (Serrano et al, 1997). Experiments conducted in transgenic mice 
carrying murine K-Ras4b
G12D
 showed that deficiency in either the p53 gene or 
the Ink4A/Arf  locus would accelerate the formation of tumours which exhibited 
more malignant features (Fisher et al, 2001).  However, the mechanism how Ras 
activates ARF has not be fully elucidated.  
Recent study in lung adenocarcinoma (ADC) revealed that the expression 
of RUNX3 has a strong protective effect against K-Ras
G12D 
(Lee et al, 2013). 
Expression of K-Ras
G12D
 would cause the development of nonmucinous lung 
adenoma (AD) and adenocarcinoma (ADC) in mice, but the combination of 
Runx3 inactivation and K-Ras
G12D
 activation leads to dramatically more serious 
lung adenocarcinoma of both mucinous and non-mucinous types, indicating that 
the combination of Runx3 inactivation and K-Ras
G12D
 activation is critical for 
the progression from adenoma to adenocarcinoma. Consistent with the mouse 
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model, in human lung adenocarcinoma samples, the rate of RUNX3 inactivation, 
either due to reduced expression or mislocalization, is much higher in samples 
carrying K-Ras or EGFR mutations, compared with the rate in samples with 
wild-type K-Ras and EGFR (Lee et al, 2013).  
Further studies carried out in human cell lines cultured in vitro revealed that 
acetylated RUNX3 physically interacts with Bromodomain-Containing Protein 2 
(BRD2), a transcriptional regulator mediating chromatin remodeling. The 
RUNX3-BRD2 complex could trigger the persistent expression of ARF and 
p21
WAF/CIP
, and this interaction is stabilized by the expression of K-Ras
G12D
, 
which exactly explains how oncogenic K-Ras triggers the ARF-p53-p21 
pathway (Lee et al, 2013).  
This novel discovery about RUNX3’s fundamental role in the initiation of 
oncogene induced senescence supports the long-term observation that RUNX3 
is frequently silenced in various kinds of cancer. RUNX3 mediates the first line 
protection against oncogenic transformation, whose malfunction paves the way 
for further disease progression (Lee et al, 2013). 
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1.4 Introduction of TEAD-YAP complex 
1.4.1 The structure of TEAD-YAP complex 
TEA domain (TEAD) proteins are a family of transcription factors sharing a 
common the TEA DNA binding domain, which recognizes and binds to a 
specific sequence (5’-CATTCC-3’) (Xiao et al, 1991). Mammals express four 
TEAD proteins, named TEAD1, TEAD2, TEAD3 and TEAD4, which are 
highly conserved (Yasunami et al, 1996; Yockey et al, 1996). At least one 
TEAD gene is expressed in most adult tissues, while in some tissues, such as 
lung, all four TEAD proteins are abundantly expressed. Even though TEAD 
proteins are highly conserved in TEA domain, each TEAD protein exhibits 
different expression patterns with respect to tissue and developmental stage 
specificity, suggesting that each protein has a unique function (Jacquemin et al, 
1998; Kaneko & DePamphilis, 1998; Yasunami et al, 1996). 
The full transcriptional activity of TEAD proteins requires the binding to 
other transcriptional coactivators, due to the lack of intrinsic transcription 
activation domain (Jiang & Eberhardt, 1996; Xiao et al, 1991). Among all the 
possible transcriptional coactivators which interact with TEAD proteins, the 
most putative and general coactivator which can trigger the transcriptional 
activity of all four TEAD proteins, is identified as Yes-associated-protein (YAP), 
a protein whose carboxyl-terminus contains an acidic transcriptional activation 
domain (Vassilev et al, 2001; Yagi et al, 1999; Zhao et al, 2008). The three-
dimensional structure of the hYAP (residues 50–171)–hTEAD1 (residues 194–
411) and mYAP (residues 39-92)-mTEAD4 (residues 210-427) complexes have 
been solved (Chen et al, 2010; Li et al, 2010). According to the protein 
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crystallography data shown in Figure 1.4, the amino terminal of hYAP wraps 
around the globular structure of hTEAD1’s carboxyl terminal via three highly 
conserved interfaces, among which the interface 3, including hYAP residues 




Figure 1.4 Overall interaction between YAP and TEAD shown as a ribbon 
representation. TEAD is shown in light blue, and different YAP elements are 
shown in yellow, green, cyan, and red. Secondary structural elements are 
labelled. (Li et al, 2010) 
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1.4.2 TEAD-YAP complex and Hippo pathway 
TEAD proteins are mainly concentrated in cell nucleus, while YAP is able 
to shuttle between cytoplasm and nucleus, and the activity of TEAD is limited 
by the level of nuclear YAP, which is under the precise control of Hippo 
pathway as well as other pathways (Huang et al, 2005; Mohler et al, 1999; Zhao 
et al, 2007). 
 In mammals, the core components of Hippo pathway consists of 
Mammalian STE20-Like Protein Kinase 1/2 (Mst1/2), Salvador Homolog 1 
(Sav1), large tumour suppressor kinase 1/2 (Lats1/2) and MOB kinase activator 
1 (Mob1) (Chow et al, 2010; Hao et al, 2008; Lee et al, 2008; Praskova et al, 
2008; Zhou et al, 2009b). Mst1/2-Sav1 complex phosphorylates Lats1/2-Mob1 
complex, and the phosphorylated Lats1/2-Mob1 complex would become active 





(Zhao et al, 2010a). The phosphorylated YAP
S127
 would be recognized by the 
14-3-3 proteins, and get sequestered in cytoplasm (Zhao et al, 2007). The 
phosphorylated YAP
S381
 would recruit CK1δ/ɛ to initiate the ubiquitination of 
YAP by SCF
β-TRCP
 E3 ubiquitin ligase, resulting in the proteasomal degradation 
of ubiquitinated YAP (Zhao et al, 2010b). Hippo pathway is highly potent in the 
controlling of nuclear YAP level since it regulates YAP in both spatial and 
temporal manners (Zhao et al, 2010a).  
 The core components of Hippo pathway are conserved from Drosophila to 
Mammals. MST’s drosophila homologue is Hpo. SAV’s drosophila homologue 
is still called as Sav. LATS’s drosophila homologue is Wts/Lats. Drosophila 
Yorkie is homologous to mammaliam YAP (Yes-Association-Protein) (Dong et 
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Figure 1.5 Models of the Hippo pathway in Drosophila and mammals. (Zhao et 
al, 2010a) 
 
Various upstream signals can regulate the activity of Hippo pathway, 
resulting in the change of TEAD-YAP activity. Cell membrane protein 
neurofibromin 2 (NF2), adherens junction protein E-Cadherin (CDH1), α-
catenin and β-catenin, as well as cell skeleton protein Fibrous Actin (F-Actin) 
are all able to enhance the activity of Hippo pathway, indicating that Hippo 
pathway is closely related with cell-cell contact and cell morphology (Kim et al, 
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2011; Konsavage et al, 2012; Wada et al, 2011; Yokoyama et al, 2008). Serum-
borne lysophosphatidic acid (LPA) and sphingosine 1-phosphophate (S1P) can 
strongly inhibit the activity of Hippo pathway through G12/13-coupled receptors, 
leading to robust activation of TEAD-YAP transcriptional activity, while the 
stimulation of Gs-coupled receptors by glucagon or epinephrine activates Hippo 
pathway, causing the reduction of TEAD-YAP activity (Cai & Xu, 2013; Yu et 
al, 2012a). The complicated regulation of Hippo pathway by different kinds of 
G protein coupled receptors (GPCRs) emphasizes the importance of 
extracellular diffusible signals in Hippo pathway. 
The activity of YAP can also be regulated by other means apart from 
canonical Hippo pathway. For example, Wnt pathway has an influence on YAP 
expression at the transcription level (Konsavage et al, 2012; Konsavage & 
Yochum, 2013). Angiomotin (AMOT) family proteins, which mainly localize 
on cell membrane and have a strong affinity to YAP, can restrict YAP on tight 
junction and enhance YAP phosphorylation (Chan et al, 2011; Zhao et al, 2011). 
Another cell membrane protein called zona occludens-2 protein (ZO-2) is able 
to bind with YAP and to improve YAP's translocation to the nucleus (Oka et al, 
2010; Oka et al, 2012). Recently, a transcriptional cofactor called VGLL4, 
which contains a TEAD-interacting domain (TDU domain) while lacks any 
transcriptional activation domain, is discovered to be able to interact with TEAD 
in the same manner of YAP, competing with YAP and reducing the 
transcriptional activity of TEAD proteins (Jiao et al, 2014; Pobbati & Hong, 
2013; Zhang et al, 2014).  
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In summary, YAP activity is under strict control of Hippo pathway as well 
as other regulatory partners through both phosphorylation and physical 
interactions, resulting in the efficient silencing of YAP activity in most 
quiescent adult cells.  
 
1.4.3 The role of TEAD-YAP complex / Hippo pathway in organ size control and 
carcinogenesis 
The crucial role of TEAD-YAP complex in organ size control was first 
discovered using Drosophila as model (Justice et al, 1995; Xu et al, 1995). 
Firstly, scientists discovered several cell proliferation suppressors, named hippo 
(hpo), salvador (sav), and warts (wts also called Lats), whose inactivation would 
result in massive expansion of cell number (Harvey et al, 2003; Jia et al, 2003; 
Pantalacci et al, 2003; Tapon et al, 2002; Udan et al, 2003; Wu et al, 2003). 
Studies from several groups all showed that these genes functioned in a common 
pathway in which Hpo, facilitated by Sav, phosphorylated Wts (Lai et al, 2005; 
Shimizu et al, 2008; Wei et al, 2007; Wu et al, 2003). This pathway was later 
named as Hippo pathway since the major phenotype after deleting any elements 
of this pathway was a significantly enlarged worm (Edgar, 2006). Later, yorkie 
(yki), the Drosophila homologue of YAP, was identified as the elusive target of 
the Wts/Lats tumor suppressor, and overexpression of yki phenocopied loss-of-
function mutations of hpo, sav, or wts (Dong et al, 2007; Oka et al, 2010). 
 In mammals, the study about the role Hippo pathway in organ size control 
was mainly done using mouse liver as model (Avruch et al, 2011). Liver was an 
organ with remarkable regenerative capacity, and the change of liver size within 
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a certain range can be tolerated by mice (Yokoyama et al, 1953). Double 
knockout of both Mst1 and Mst2 in liver would cause liver enlargement, tumour 
formation and oval cell accumulation (Lu et al, 2010; Song et al, 2010; Zhou et 
al, 2009a). Double knockout of Sav1 in liver would lead to liver enlargement 
and single formation of tumours probably from oval cell origin (Lee et al, 2008; 
Lu et al, 2010). YAP overexpression in liver would cause enlarged liver size, 
cancer development and expansion of progenitor cells, while knockout of Yap in 
liver led to slightly enlarged liver with injury and fibrosis, loss of biliary 
epithelial cells and increased hepatocyte turnover (Camargo et al, 2007; Dong et 
al, 2007). A summary of the phenotype after Yap hyperactivation by deleting 
different components of Hippo pathway is shown in Table1.2. 
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Table 1.2 Description of the different phenotypes after overexpressing YAP or 
inactivation of the Sav1 and Mst1/2 in mouse liver (Avruch et al, 2011). 
  
- 36 - 
 
 YAP deregulation also has a strong impact on other organs. For example, 
forced expression of a constitutively active form of Yap in the embryonic heart 
increases cardiomyocyte number and heart size (Xin et al, 2013). YAP 
expression can also expand basal epidermal progenitors in mouse skin and 
inhibit their terminal differentiation (Beverdam et al, 2013; Zhang et al, 2011). 
Inactivation of YAP in colon causes no obvious intestinal defects under normal 
homeostasis, but severely impairs dextran sodium sulfate (DSS)-induced 
intestinal regeneration, while hyperactivation of YAP in colon by colon specific 
knock out of Sav1 would result in widespread early-onset polyp formation 
following DSS treatment (Cai et al, 2010).  
 These data clearly point out the important role of Hippo pathway in organ 
size control, tissue regeneration and cancer development. The emerging role of 
Hippo pathway in cancer has become more and more recognized these days. 
Reduced MST1 and MST2 expression was observed in human hepatocellular 
carcinomas, soft-tissue sarcoma and colorectal cancer (Seidel et al, 2007; Zhou 
et al, 2009a; Zhou et al, 2011). Down-regulation and mutations of LATS1 and 
LATS2 was observed in breast cancer, lung cancer and astrocytoma (Jiang et al, 
2006; Sasaki et al, 2010; Takahashi et al, 2005). Abnormally high expression or 
increased nuclear localization of YAP is frequently observed in major human 
cancers like liver cancer, breast cancer and lung cancer (Su et al, 2012; Wang et 
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1.4.4 TEAD-YAP complex and gastric cancer 
 According to the result of immunohistological studies performed using 
gastric cancer specimen, YAP expression is significantly up-regulated in gastric 
carcinoma as well as precancerous lesions, and YAP overexpression has a 
positive correlation with the overexpression of survivin, a member of the 
inhibitor of apoptotic protein (IAP) family (Da et al, 2009; Zhang et al, 2012). 
YAP overexpression or nuclear accumulation is also correlated with poor 
prognosis for gastric cancer patients, due to YAP ’ s role in promoting 
proliferation, anchorage-independent colony formation, cell invasion and cell 
motility , which is shown by ectopic expression or knockdown experiments 
performed in gastric cancer cell lines (Kang et al, 2011).  
 According to a recent report studying gene expression pattern of gastric 
cancer specimens utilizing both epigenomic and transcriptomic approaches, 
TEAD4 upregulation due to reduced promoter methylation has a significant 
association with poor prognosis of gastric cancer patients. Knockdown of 
TEAD4 results in the reduced growth of gastric cancer cells both in vitro and in 
vivo, since TEAD4 triggers the expression of various genes in favour of cell 
proliferation and migration (Lim et al, 2014).  
 Currently, our understanding about the role of TEAD-YAP complex in 
gastric cancer is still mainly based on observations other than the study on the 
mechanism. More thorough research should be conducted to explain the cause 
of TEAD-YAP hyperactivation in gastric cancer as well as the tissue specific 
biological functions of TEAD-YAP complex in stomach. 
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1.4.5 The development of TEAD-YAP antagonists with potential clinical 
applications 
 Some antagonist targeting TEAD-YAP complex has already been 
developed for their potential application as cancer treatment. In a screening 
using the Johns Hopkins Drug Library, which is a collection of >3300 drugs that 
have been approved by the United States Food and Drug Administration or its 
foreign counterparts or have entered phase II clinical trials, two small molecular 
compounds, named protoporphyrin IX (PPIX) and verteporfin (VP) were 
identified to be able to effectively disrupt the interaction between TEAD and 
YAP (Liu-Chittenden et al, 2012b). When VP was tested in mice bearing liver-
specific knockout of NF2/Merlin, which exhibited bile duct overproliferation 
due to activation of endogenous YAP, the liver overgrowth was suppressed by 
VP treatment (Liu-Chittenden et al, 2012b).  
 A peptide called Super-TDU, which mimicked the TEAD interaction 
domain of VGLL4, was tested on both human primary gastric tumour cells as 
well as a gastric cancer mouse model treated with H. pylori and a cocarcinogen 
called N-methyl-N0-nitro-N-nitrosoguanidine (MNNG). This Super-TDU 
peptide showed dramatic inhibition on tumour cells’ growth in both systems 
without obvious systematic toxicity (Jiao et al, 2014).  
 The potent effects of TEAD-YAP antagonists on animal cancer models 
revealed the importance of TEAD-YAP complex in the progression of cancer, 
which might have a broader application in targeted cancer therapies in the near 
future, since this oncogenic complex is usually inactive in normal adult tissues 
(Jiao et al, 2014).  
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1.5 The interaction between YAP and RUNX proteins 
YAP-RUNX interaction is among the earliest protein-protein interactions 
identified for YAP. In 1999, YAP was identified as a potential binding partner 
for RUNX proteins in a yeast two-hybrid screening. Further analysis revealed 
that the tryptophan-tryptophan (WW) domain of YAP, could bind with the PY 
motif (PPxY) located at the carboxyl terminal of RUNX proteins (Chen & Sudol, 
1995; Sudol et al, 1995). Via its strong intrinsic transcription activation domain, 
YAP could function as a strong transcription coactivator for RUNX proteins on 
the osteocalcin promoter (Yagi et al, 1999).  
Later, the interaction between RUNX2 and YAP was described in 
osteoblast cells. The RUNX2-YAP interaction was crucial for regulating 
osteocalcin expression under the control of Src/Yes tyrosine kinase signalling 
during the skeleton development, since Src could phosphorylate YAP and 
weaken the binding between YAP and RUNX2, causing the reduction of 
osteocalcin expression (Zaidi et al, 2004).  
 It is now recognised that TEAD-YAP complex plays a crucial role in organ 
size control as well as cancer progression, so the interaction between RUNX3 
and TEAD-YAP complex warrants re-examination for a more comprehensive 
understanding of the regulation and function of TEAD-YAP complex.  
  





Chapter 2  
Materials and Methods 
 
  
- 41 - 
 
2.1 Cell Culture 
 HEK293T cell line, HS746T gastric cancer cell line and AZ521 gastric 
cancer cell line were maintained in Dulbecco’s modified Eagle’s media (DMEM, 
Nacalai tesque) with 10% fetal bovine serum (FBS, Hyclone), 100 U/ml 
penicillin and 100μg/ml streptomycin antibiotics (Life Technologies). YCC1 
and YCC6 gastric cancer cell lines were maintained in OPTI-MEM media (Life 
Technologies) with 10% FBS, 5mM Sodium Pyruvate (Life Technologies), 100 
U/ml penicillin and 100μg/ml streptomycin antibiotics. The other gastric cancer 
cell lines used in this thesis (including MKN28, MKN74, AGS, NUG-C3, 
NUG-C4, NCI-N87, HS746T, MKN45, HGC27), were maintained in RPMI-
1640 media (Nacalai tesque) with 10% FBS, 100 U/ml penicillin and 100μg/ml 
streptomycin antibiotics. 
 
2.2 Plasmid and siRNA transfection 
 esiRNA human YAP1 was purchased from Sigma-Aldrich under catalogue 
number: EHU113021-50UG. esiTEAD1 RNA was purchased from Sigma-
Aldrich under catalogue number: EHU079871-50UG. esiRNA control was 
purchased from Sigma-Aldrich under catalogue number: EHUEGFP-50UG. The 
siRUNX3 (LU-012666-00-0002, set of 4) and siScramble (D-001810-10-50, set 
of 4) were purchased from Thermo. 
 Plasmid transfection was performed using Lipofectamin 2000 (life 
technologies) according to manufacturer’s instructions. For every 1 µg of 
plasmid, 2 µl Lipofectamin 2000 was used to achieve a desired transfection 
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efficiency. siRNA transfection (including esiRNA) was performed using 
Lipofectamin iMAX (Life Technologies). For every 20 pmol of siRNA, 1 µl 
Lipofectamin imax was used to achieve a desired knocking down efficiency. 
  The oligos were diluted in serum free media and mixed with Lipofectamin 
2000 or Lipofectamin iMAX, incubated at room temperatrue for 20 min, then 
added into the cells.  
 
2.3 Retrovirus particles preparation and infection  
 Retrovirus was packaged using HEK293T cells. Retrovirus vectors and 
pCL10A packaging vector were cotransfected to HEK293T cells at 1 : 1 ration. 
The supernatant containing retrovirus particles was harvested at 48 hours and 72 
hours after transfection. The supernatant was filtered through 0.45 µm filter 
units. The filtered supernatant containing virus particles could be used directly 
for infections or aliquoted and stored in -80 °C freezer for long-term storage. 
 For retrovirus infection, target cells were seeded at 30% confluence. 
Filtered HEK293T supernatant containing retrovirus was mixed with fresh 
media at 1 : 1 ratio and polybrene was added to a final concentration of 5 ng/µl. 
This mix was added to the target cells and kept overnight, then replaced with 
fresh media. Target cells would undergo two rounds of overnight infections 
followed by drug selection (puromycin or hygromycin according to the 
requirement of vector) at the minimal dose which could kill all uninfected cells 
within 48 hours. After 2 days of selection, the remaining cells would be 
recovered in fresh medium without selection drugs for 1 day, and then they 
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would be used for downstream assays. 
 For TEAD1/3/4 knocking down experiment, shRNA retrovirus plasmids 
were obtained from Origene Technologies. Forward oligo sequences are listed in 
the 5’-3’ direction: ShTEAD1/3/4: GATCAACTTCATCCACAAGCT; 
shScramble: GCACTACCAGAGCTAACTCAGATAGTACT. 
 
2.4 Protein preparation and Western blot 
 For protein preparation, cell pellets were lysed in lysis buffer, containing 
20mM Tris PH8, 150mM NaCl, 10% glycerol, 0.1% NP-40, 0.1mM EDTA 
proteinase inhibitor cocktail (Roche), 1mM DTT and Benzonase nuclease 
(Novagen) on ice for 45 minutes. The cell lysates were centrifuged at 12,000 
rpm for 10 minutes at 4°C, and  the supernatents, which contained all the soluble 
proteins in the cell pellets, were collected into fresh microfuge tubes.  
 The amount of protein was quantified using Bradford Assay. Briefly, 2ul of 
cell lysate was mixed with 1ml Bradford dye and incubated for 5 minutes at 
room temperature prior to measurement using GeneQuant 1300 
spectrophotometer (GE Healthcare). The absorbance at 595nm would be 
recorded and the protein concentration would be determined using a standard 
curve by standard proteins with known concentrations.  
 After quantification, the amount of proteins was normalised against the 
most diluted sample before the addition of SDS-containing loading buffer. Cell 
lysates were heated at 100°C for 10 minutes to denature the proteins.  
 Whole cell lysates were resolved in 10% SDS-polyacrylamide gels and 
- 44 - 
 
electrophoresed at 100V for approximately 2 hours. Proteins were transferred 
onto PVDF membranes (Biorad) at constant 100V for 2 hours prior to blocking 
using 5% skim milk in PBST (PBS containing 0.1% tween, Sigma-Aldrich) for 
1hour.  
 Primary antibodies were diluted using 5% skim milk in PBST and 
incubated with the PVDF membrane overnight at 4°C, and were washed away 
using PBST 3 times for 30 minutes. After washing, the secondary antibodies 
which were diluted using 5% skim milk in PBST were applied to the membrane. 
After 1 hour of incubation at room temperature, the secondary antibodies were 
washed away using PBST 3 times for 30 minutes. Then chemiluminescent 
signals were captured using Immobilon Western Chemiluminescent HRP 
substrate reagents (Millipore).  
 The antibodies used in this thesis were listed in the chart below (Tab 2.1). 
Antibody Company Catalog Number 
HA (Y-11) Santa Cruz sc-805 
GFP (FL) Santa Cruz sc-8334 
YAP (H-125) Santa Cruz sc-15407 
TEF1(H-4)X Santa Cruz sc-37611X 
Myc (9E10) Santa Cruz sc-40 
TEAD3 Abcam ab75192 
TEAD4 Abcam ab58310 
α-Tubulin (DM1A) Sigma T9026 
β-Actin (AC-74) Sigma A5316 
Flag M2 Sigma F3165 
Flag M2 Rabbit Sigma F7425 
RUNX3 (R3-5G4) MBL D235-3 
CBFBeta MBL D127-3 
GAPDH (14C10) Cell Signaling Technology 2118S 
TEAD1 BD BioScience 610923 
 
Table 2.1 The antibodies used for western blot detection in this thesis.  
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2.5 Immunoprecipitation (IP) 
2.5.1 Endogenous IP 
 Endogenous immunoprecipitation using RUNX3 antibody (R3-6E9, MBL) 
was performed using HGC27 gastric cancer cells. The IP buffer contains 20mM 
Tris PH8, 150mM NaCl, 10% glycerol, 0.1% NP-40, 0.1mM EDTA proteinase 
inhibitor cocktail (Roche), 1mM DTT and Benzonase nuclease (Novagen).  
 Megnatic Protein A+G beads (Millipore) was pre-coated with antibodies 
overnight in 300 µl IP buffer containing 5mg/ml BSA as blocking reagent at 
4°C. 4 µg of RUNX3 monoclonal antibody (6E9) was used to incubate with 
20ul of Megnatic Protein A+G beads slurry (50% slurry), while 4 µg of normal 
mouse IgG was used as control at the same setting. The antibody-bond beads 
(named as anti-RUNX3-beads or mouse-IgG-beads) were washed three times 
with chilled IP buffer before usage.  
 HGC-27 cell line was cultured in 150mm dish to a confluency of 70%. One 
dish of cells were harvested by trypsin digestion, and washed with chilled PBS 
once. The cell pellet was lysed in 2.5 ml of IP buffer. After 3 times of brief 
sonication (3 seconds/time, output set at 3, microsonTM Ultrasonic Cell 
Disruptor), the lysate was incubated on ice for 45 min, and centrifuged at 12’000 
rpm in a chilled centrifuge (TOMYTM, MX-305) to remove all the debris. 30 µl 
cell lysate was mixed with 10 µl 4X Laemmli Sample buffer, boiled at 100 °C 
for 10 min and kept as input control.  
 1 ml of cell lysate (protein concentration at about 1mg/ml) was used for one 
IP sample to incubate either with anti-RUNX3-beads or mouse-IgG-beads at 
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4 °C for 1 hour. After the incubation, the beads were washed with 1 ml chilled 
IP buffer for 6 times, and boiled in 40 ul of 1X Laemmli Sample buffer at 
100 °C for 10 min. The supernatants were collected and used for Western blot 
analysis. 
2.5.2 Exogenous IP 
 HEK293T cell was cultured to 40% confluent in 100mm dish, and 
transfected with plasmids according to the needs of experiments. After 24 hours, 
cells were harvested by trypsin digestion and washed with chilled PBS once. 
Cell pellet was lysed using 450 µl IP buffer/sample (same IP buffer used for 
endogensou IP) and kept on ice for 45 min. The debris was removed by 
centrifuging at 12’000 rpm in a chilled centrifuge (TOMYTM, MX-305). 30 µl 
of cell lysate was mixed with 10 µl 4X Laemmli Sample buffer, boiled at 100 °C 
for 10 min and kept as input control. The remaining 400 ul cell lysate was 
incubated with 20 ul agarose beads (50% slurry) conjucated with different tag 
antibodies. The tubes were kept with constant rotation at 4 °C for 2 hours. After 
the incubation, beads were washed with 1 ml chilled IP buffer for 6 times, and 
boiled in 40 ul of 1X Laemmli Sample buffer at 100 °C for 10 min. The 
supernatant was collected and used for Western blot analysis. 
 The agarose beads conjugated with tag antibodies used in this thesis were 
listed in the chart below (Tab 2.2). 
Antibody Company Catalog Number 
Flag M2 beads Sigma A4596 
GFP beads Chromotek gta-100 
HA beads Roche 11815016001 
 
Table 2.2 The agarose beads conjugated with tag antibodies used in this thesis. 
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2.5.3 Sequential IP 
 The Flag-RUNX3, GFP-YAP and HA-TEAD4 proteins were prepared 
using TnT® Quick Coupled Transcription/Translation System (Promega) as 
describe in Chapter 2.17. The final volume of protein product mixture was 56 µl. 
25 µl of each protein was used for one IP mixture, and the total volume was 
topped up with chilled IP buffer to 400 µl. 12 µl of the IP mixture was kept 
separated (4 ul of 4X Laemmli Sample  buffer was added) as input control for 
the first round of IP, and the rest IP mixture was incubated with 20 µl Flag-M2 
agarose beads at 4 °C for 1 hour.  
 The beads were washed for 6 times with IP buffer, and all the bound 
proteins was eluted with 100 ul IP buffer containing 3X Flag Peptide (500 µg/ml) 
at 4 °C for 1 hour. 5 µl of the eluted product was kept separated (2 ul of 4X 
Laemmli Sample  buffer was added) as the input control  of the second round of 
IP, and the rest 95 µl elute was incubated with GFP beads at 4 °C for 1 hour. 
Then the GFP beads were washed with IP buffer for 6 times, and boiled in 30 ul 
of 1X Laemmli Sample buffer at 100 °C for 10 min.  
 16 µl of input control of first IP, 7 µl of input control of second IP and 30 ul 
of final IP products were loaded to SDS-PAGE for antibody detection. 
 
2.6 Immonohistochemistry (IHC) 
 The paraffin fixed slides were offered by Prof. Yeoh Khay Guan’s group in 
National University Hospital. 
 In IHC experiments, after deparaffinization and rehydration, antigen was 
- 48 - 
 
retrieved in retrieval solution (Target Retrieval Solution, DAKO) at 100 °C for 
20min. After 3 washes in PBS, endogenous peroxidase activity was blocked by 
incubating with 1% H2O2 for 15min at room temperature. The slides were 
washed with PBS (3 X 5min) and then incubated with blocking buffer (DAKO) 
for 1hour at room temperature. 
 Primary antibodies were diluted in the blocking buffer (DAKO) at proper 
concentration (YAP, cell signalling, 1A12, 1:400; TEAD1, LSBIO, LS-B6651, 
1:100), added on the top of slides and incubated in a humid box at 4 °C 
overnight. The slides were washed in PBST (3 X 5min) and incubated with 
secondary antibody (DAKO, polymer HRP-labelled anti mouseEnvision) for 1 
hour at room temperature. After 3 washes using PBST, DAB (3,3'-
Diaminobenzidine, DAKO) substrate was used to detect the bound peroxidase 
on the slides.  
 
2.7 Dual-luciferase reporter assay 
 HEK293T cells were cultured to 40% confluent in 24-well plates, and 
transfected with plasmids according to experiment design. Triplication was 
made for each sample. After 24 hours, cells were lysed in 50 µl passive lysis 
buffer, and the luciferase activity was measured using Dual-Luciferase® 
Reporter Assay System (Promega) according to manufacturer’s instructions.  
 Briefly, 10 µl of cell lysate was mixed with 50 µl of LAR II solution and 
the tube was placed into GloMax® Single-Tube Multimode Reader (Promega) 
to measure the light generated by firefly luciferase. The same tube was taken out 
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and 50 µl of Stop and Glo reagent was added and mixed. It was placed back to 
the reader for the measurement of the light generated by renilla luciferase. The 
ratio between Firefly and Renilla luciferase activity was calculated and 
normalized according to the value of vector control. 
 
2.8 Electrophoretic Mobility Shift Assay (EMSA) 
 EMSA was performed using LightShift Chemiluminescent EMSA Kit 
(Thermo) according to manufacturer’s instructions. The forward oligo of TEAD 
probe (5’-3’) was TTCGGGACCAGGCCTGGAATGTTTCCACC/Biotin/. 
 The buffer for EMSA was 1X TGE buffer. To prepare 1 liter of 5X TGE 
buffer, 30.28 g of Tris base, 142.7 g Glycin, 3.72 g EDTA were dissolved in 
water and the final volume was adjusted to 1 litre. The 6% EMSA gel (10ml) 
was prepared by mixing 5.7 ml H2O, 2 ml 30% acrylamide/Bis solution, 2 ml  
5X TGE buffer, 200 µL 10% APS, 20 µL TEMED. 
 The EMSA reaction mix was prepared by mixing 1 µL 10X binding buffer, 
0.5 µL 1µg/μL Poly (dI•dC) , required amount of HA-TEAD4-1-125 protein and 
Flag-RUNX3 protein, HA antibody if required, and H2O till the total volume 
reached 8 µL. After incubating it on ice for 15 minutes, 2 µl 0.1 pmol/µl TEAD 
probe was added to obtain the final reaction mix, which would be loaded on the 
gel after incubating on ice for 30 minutes. 
 All the gel running and transferring steps were carried out at 4°C. The gel 
was pre-run in 1X TGE buffer at 65V for 30 minutes, and the reaction mix was 
loaded to the gel, run at 65V for another 90 minutes. The gel was transferred to 
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Hybond N+ membrane (GE health care) in 1X TGE buffer at 100V, 350mA for 
1 hour. The membrane and DNA probes on it were crosslinked using 
Stratalinker (Stratalinker® UV Crosslinker) for 10 minutes.  The blocking, 
labelling and detection steps were all conducted according to the instructions of 
LightShift Chemiluminescent EMSA Kit (Thermo). 
 
2.9 Transcription factor enrichment experiment 
 Transcriptional Factor Enrichment Experiment was performed as previously 
described (Oh et al, 2013). Briefly, 10ul streptavidin conjugated agarose beads 
(Thermo) were used for each sample. The beads were washed with PBS briefly 
twice. Then beads were preabsorbed with the blocking/coupling buffer for 30 
min at room temperature with constant rotation. 100ul blocking buffer was used 
for every 10ul beads. The beads were dispensed into individual tubes together 
with the blocking buffer (about 100ul mix/ tube). 7ul biotin label probe (0.1 
pmol/µl) was added into each tube, and incubated for 30 min at room 
temperature with constant rotation. At this stage, the beads were already coated 
with DNA probes. These beads were washed three times with 1X 
oligonucleotide binding buffer before usage.  
 The reaction mix (300 µL scale) was prepared by mixing 3 X 
oligonucleotide binding buffer with cell nuclear extraction. The reaction mix 
was incubated with probe-coated beads for 3 hours in cold room. Then the beads 
were washed three times with 1ml of 1X oligonucleotide binding buffer, and 
boiled in 40 ul of 1X Laemmli Sample buffer at 100 °C for 10 min.  All 
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precipitated proteins were preserved in the final supernatant, which could be 
resolved using SDS-gels. 
 The compositions of buffers were listed below. 
 Oligonucleotide binding buffer (3 X OBB) : 36mM HEPES, pH7.9, 12mM 
Tris, 450mM KCL, 36%Glycerol, 3mM EDTA, 3mM DTT. 
 Blocking/coupling Buffer (3ml): 3X OBB 1ml, 5mg/ml BSA 1.2ml, 
0.5mg/m dIdC 60ul, 10mg/ml Salmon Sperm DNA 60ul, 10%NP-40 60ul, 
DDW 620ul. Add proteinase and phosphotase inhibitor or DTT if necessary. 
 Reaction Buffer (3ml): 3XOBB 1ml, 5mg/ml BSA 1.2ml, 0.5mg/ml dIdC 
60ul, 10%NP-40 60ul, DDW plus protein: 680ul. Add proteinase and 
phosphotase inhibitor or DTT if necessary. 
 The forward oligo of TEAD probe (5’-3’) was 
TTCGGGACCAGGCCTGGAATGTTTCCACC/Biotin/. The forward oligo of 
TEAD mutated probe (5’-3’) was 
TTCGGGACCCAGGCCTAGAATGTTTCCACC/Biotin/. The biotin 
conjugated probes were annealed with the reverse complementary non-biotin 
conjugated probes to generate double strand probes. 
 
2.10 Purification of RNA using Trizol 
 Cells were rinsed with cold PBS once and directly lysed in Trizol reagent 
(Life Techologies). 1 ml of Trizol reagent was used for every 3.5 cm diameter 
dish. Pass the cell lysate several times through a 1ml pipette tip, and collect all 
the lysate in the dish into fresh eppendorf tubes.  
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 0.2 ml of chloroform was added into every 1 ml of Trizol lysate. The mix 
was votexed vigorously for 15 seconds and incubated at room temperature for 3 
min. The samples were spin at 12’000g for 15 min at 4 °C. The colourless upper 
aqueous phase was collected, and mixed with equal volume of isopropanol. 
Then the samples were incubated at room temperature for 10 min and spin at 
12’000g for 10 min at 4°C. At this stage, the RNA precipitant formed a gel-like 
pellet on the side and bottom of the tube, which should be washed with at least 1 
ml of 75% ethanol. The RNA pellet was air-dried after washing, and dissolved 
in RNAse free water. 
 The yield of RNA was measured by NanoDrop 1000 Spectrophotometer 
(Thermo Fisher Scientific, MA, USA). 
 
2.11 Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) 
 Complementary DNA (cDNA) was synthesized from 2.0μg of total RNA 
using SuperScript II Reverse Transcriptase (Life Technologies). The reaction 
mixtures were prepared according to the manufacturer’s instructions and 
incubated at 42°C for 50 min. The reverse transcriptase was inactivated at 70°C 
for 15min. 
 Quantitative PCR was performed in 7500 Real-time PCR system using 
Power SYBR Green Master Mix (Applied Biosystems, CA, USA) and 2μl of 5X 
diluted cDNA as template.  
 The list of gene-specific oligonucleotide primers used for SYBR Green-
based measurements were shown below (Tab 2.3). 
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Table 2.3 gene-specific oligonucleotide primers used for SYBR Green-based 
real-time PCR. 
 
2.12 Chromatin Immunoprecipitation (ChIP) 
 ChIP was performed using TEAD1 antibody (sc-376113 X, Santa Cruz) and 
Magna ChIP™ A/G Chromatin Immunoprecipitation Kit (Millipore) according 
to manufacturer’s instructions.  
 Briefly, 2 X 10
6
 cells were used for each sample. Proteins were crosslinked 
to DNA by adding formaldehyde directly to culture medium to a final 
concentration of 1% and incubate for 10 minutes at room temperature. Aspirate 
medium, wash and scrape cells with ice cold PBS containing protease inhibitors.  
Cells were spin for 4 minutes at 700 x g at 4°C.  
 Cell pellets were resuspend in 100µl SDS Lysis Buffer for 10 minutes on 
ice. Lysate was sonicated to reduce DNA length to 500 basepairs using 
Bioruptor® Plus (Diagenode) with the programme set as 25 cycles of 30 
seconds high output sonication  followed by 30 seconds rest at 4°C. Debris was 
removed by centrifugation for 10 minutes at 13,000 rpm at 4°C in a 
microcentrifuge. Supernatant was diluted by 10 fold with ChIP Dilution Buffer 
and split equally into two tubes. Either 2 mg TEAD1 antibody or 2 mg normal 
mouse IgG was added and incubated with the lysates overnight at 4°C. 
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 On the next day, antibodies were immobilized by adding 10 ul of Magna 
ChIP™ A/G beads (bed volume) and incubating for 1 hour at 4°C. The beads 
were washed for 5 minutes using the following buffer: Low Salt Immune 
Complex Wash Buffer, High Salt Immune Complex Wash Buffer, LiCl Immune 
Complex Wash Buffer, 1X TE. Then the ChIP products were eluted from the 
beads twice using 250µl elution buffer at room temperature for 15 minutes. The 
elute products were combined. 20µL 5M NaCl was added into the elute products, 
and incubated at 65°C for 4 hours to reverse the protein-DNA crosslink. After 
that, 10µl of 0.5M EDTA, 20µl 1M Tris-HCl, pH 6.5 and 2µl of 10mg/ml 
Proteinase K were added to the elute products and incubated for one hour at 
45°C.  
 DNA was recover from the digested elute products by phenol/chloroform 
extraction followed by ethanol precipitation. DNA pellets were washed with 70% 
ethanol and air dried. The DNA pellets were dissolved with 50 µl DNAse free 
water.  Real-time PCR was performed using 2µl product as template for each 
reaction. 
 The CTGF promoter primers were: CTGF ChIP Forward 5-
ATATGAATCAGGAGTGGTGCGA-3; CTGF ChIP Reverse 5-
CAACTCACACCGGATTGATCC-3. (Zhao et al, 2008) 
 
2.13 Cell viability assay 
 Cell viability was measured using Cell Proliferation Reagent WST-1 
(Roche) according to the manufacturer’s instructions. 
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 Briefly, 1000-2000 cells/well were seeded in each well of 96-well plates. 
(Seeding number was dependent on cell lines, and triplication was prepared for 
each sample.) At 0 hour, 24 hours, 48hours, 72 hours and 96 hous, 10 µl of 
WST-1 reagent was added into each well and incubated in CO2 gas incubator for 
2 hours. Light absorption at 450nm (620nm as reference) was determined using 
spectrophotometer (Infinite 200, Tecan
TM
).  
 After removing basal absorbance caused by culture medium, the absorbance 
of 0 hour was used to adjust all samples to the same starting point. Then the 
values of following days would be adjusted accordingly. The adjusted 
absorbance would be used for the plotting of growth curve using Prism5 graph 
pad software. 
 
2.14 Soft agar assay 
 Soft agar assay was performed using low melting agarose (Life 
Technologies). The basal agar was prepared by mixing hot 0.8% low melting 
agarose with 2X DMEM (or 2X RPMI-1640, according to the culture condition 
of each cell) at 1:1 ratio. 1ml basal agar was added to each well of a 12-well 
plate. 
 After the basal gel was set, the top agar, which contained 0.4% low melting 
agarose, 1X DMEM (or RPMI-1640) and 10% FBS, would be prepared by 
mixing 2X DMEM (with 20% FBS) and 0.8% low melting agarose at 1 : 1 ratio. 
Every component of top agar should be balanced to 37°C before mixing, and the 
mixed top agar should be kept at 37°C till usage.  
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 2000 cells were seeded into each well of a 12-well plate (triplication should 
be prepared). The cells were dissolved in 400 µl of top agar, mixed thoroughly 
and added onto the bottom agar. The seeded plate would be kept at 4°C for 30 
minutes to ensure that the top agar had been completely set. Then fresh culture 
medium would be added on the top of the agar to keep moisture, which should 
be changed twice every week. PBS should also be added into the empty space 
between wells to keep moisture. 
 After 2 to 4 weeks, colonies would become visible for bare eyes.  They 
could be stained with 0.005% crystal violet for 4 hours, distained with PBS for 2 
days till the agar become colourless. Then pictures were taken by dissection 
microscope (SZX16, Olympus). 
 
2.15 Prokaryotic protein expression and purification 
 cDNA of HA-TEAD4 fragments were cloned into PGEX-4T-1 vector (GE 
healthcare), and transformed into Rosetta™(DE3) cells. Positive clones were 
picked from LB plates and inoculated into 3ml LB broth, cultured with 225 rpm 
shaking at 37°C overnight. The small culture was expanded to 200 ml LB broth, 
and cultured with 225 rpm shaking at 37°C till the OD 600 reached 0.8. 200ul 
0.1M IPTG was added to induce the protein production at 37°C. After 3 hours of 
induction, the bacteria were harvested by centrifuging at 8000rmp for 15 
minutes. The pellet could be stored in -80°C freezer if necessary. 
 The pellet was resuspended in 20ml cold PBS (with 100 µM PMSF and 
1mM DTT), and sonicated at output 3 for 30 seconds using ultrasonic cell 
disrupter (Microson
TM
) for 3 times, while the lysate was kept chilled on ice all 
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the time. TritonX-100 was added to the sonicated lysate to a final concentration 
of 1%, and the cell lysate was rotated in cold room for 1 hour. Then the cell 
lysate was centrifuged at 20’000 rpm for 30 minutes at 4°C to remove all the 
debris. 
 The supernatant was collected and 200ul Gluthatione Sepharose (GE 
Healthcare) was added into it and incubated with constant rotation for 1 hour in 
cold room. Then the Gluthatione Sepharose was collected by brief spinning, and 
washed 3 times with chilled PBS. The GST-fusion proteins were now 
immobilized on the Gluthatione Sepharose, which could be cleaved from the 
beads by incubating with thrombin (GE Healthcare, 0.1U/ml to 1U/ml, 
dependent on the amount of protein) at room temperature for 2 hours. The beads 
could also be directly used for downstream applications like GST pull down 
assay. 
2.16 GST pull down assay 
 GST fusion proteins were expressed and immobilized on GSH beads as 
described in Chapter 2.15. A small aliquot of beads from each sample was 
boiled in 1X Laemmli Sample buffer at 100 °C for 10 min. The proteins were 
resolved on SDS-PAGE gel and the gel was stained with Coomassie Blue 
staining solution for 1 hour, and distained with distain buffer for 3 hours. The 
relative protein amount could be determined by comparing the band intensity of 
each protein, and they should be normalized to the protein with lowest yield. 
 For each sample, only 1-4 µl of GSH beads coated with protein were used 
(exact amount for each sample should be adjusted according to the protein yield 
to guarantee same level of protein input for all samples). The beads volume was 
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topped up to 10 µl with empty GSH beads for easier handling. The beads were 
mixed with IP buffer containing the proteins of interest (either cell lysis or 
diluted purified proteins), and incubated with constant rotation for 1 hour at 4 °C. 
The beads were washed 3 times with IP buffer and boiled in 1X Laemmli 
Sample buffer at 100 °C for 10 min. All the proteins which precipitated together 
with GST fusion proteins could be analyzed with Western blot. 
 
2.17 Eukaryotic protein expression 
 Myc-TEAD1, Flag-RUNX3, GFP-YAP, HA-TEAD4 proteins were 
synthesized using TnT® Quick Coupled Transcription/Translation System 
(Promega).  
 The reaction mixture contained 7µl water, 40µl TNT® Quick Master Mix, 
1 µl 1mM Methionine, 2µl 0.5mg/ml plasmid DNA template. The reaction mix 
was incubated at 30°C for 90 minutes. Then 5.5 µl 10X DNAse reaction buffer 
and 1µl DNAse I (Promega) were added and incubated at room temperature for 
30 minutes to remove plasmid templates.  
 The final mixture contains eukaryotic proteins synthesized by rabbit 
reticulocyte extract, which can be used for other applications like the study of 
protein-protein interaction in vitro. 
 
2.18 Chemical transformation of Escherichia coli 
 Three microlitres of ligated products or one mirolitre of purified plasmid 
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was added into 50μl of home-made chemically-competent Escherichia coli 
XL10-Gold strain originally obtained from Stratagene (CA, USA). The mixture 
was kept on ice for 30min prior to heat-shock at 42°C for 90 seconds. Then the 
mixture was incubated on ice immediately for 5min and recovered in 800μl 
Luria-Bertani (LB) medium at 37°C with constant shaking for 1h.  
 The transformation mixture was subsequently plated onto LB agar plates 
containing 100μg/ml of ampicillin (Sigma-Aldrich, MO, USA) or 50 μg/ml 
kanamycin (Sigma-Aldrich, MO, USA) and incubated overnight at 37°C for 
selection of successfully transformed bacterial cells. 
 
2.19 Purification of plasmid DNA 
 DNA purification was performed at small-scale from 3ml of starter cultures 
with QIAprep Spin Miniprep columns (QIAGEN, Hilden, Germany) or large-
scale from 50ml of overnight cultures with QIAfilter Plasmid Midi kit 
(QIAGEN, Hilden, Germany) according to manufacturer’s protocols.  
 The yield of plasmid was measured using NanoDrop 1000 
Spectrophotometer (Thermo Fisher Scientific, MA, USA). 
 
2.20 Statistical analysis 
 Experimental data are presented as the mean±standard deviation (SD). All 
statistical analyses were performed using analysis of a two-tailed Student’s t test 
with GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA). Survival 
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curves were calculated using the Kaplan-Meier method. Differences were 
considered statistically significant when P values were less than 0.05. * indicates 
P<0.05; ** indicates P<0.01; *** indicates P<0.001; 
  





Chapter 3  
The direct protein-protein interaction between 
RUNX3 and TEAD proteins 
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3.1 Introduction 
In this chapter, the protein-protein interaction between RUNX3 and TEAD 
proteins (mainly TEAD1 and TEAD4) would be examined in depth. The major 
experimental approach which was used in this chapter was immunoprecipitation, 
a technique of precipitating a protein antigen out of solution using an antibody 
that specifically binds to that particular protein. In a mild solution without strong 
detergent like SDS, the protein complexes containing this antigen can be 
preserved, so they can be specifically pulled down by this antibody. The 
antibody can be further enriched using agarose or magnetic beads coated with 
Protein A (originated from bacterium Staphylococcus) or Protein G (originated 
from bacterium Streptococcal), both of which showing strong affinity to 
Immunoglobulin. The total precipitant, which contains all the components 
having protein-protein interactions with the precipitated antigen, could be 
analyzed with techniques like Western Blot. 
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3.2 RUNX3 and TEAD1 can coexist in the same complex 
In previous studies, it was already shown that RUNX3 and YAP had 
physical interaction with each other. Since TEAD proteins and YAP had strong 
protein-protein interaction with each other, it was highly possible that TEAD 
proteins and RUNX3 could coexist in the same protein complex. I wanted to test 
this hypothesis by performing endogenous immunoprecipitation (IP) in HCG-27 
gastric cancer cell line, in which both RUNX3 and TEAD1 proteins were 
expressed at a high level. 
 The immunoprecipitation was performed using a monoclonal antibody 
targeting RUNX3 (clone 6E9) or normal mouse IgG control as described in the 
Chapter 2.5. For the detection of RUNX3, a special Biotin-labled primary 
antibody (clone 5G4) was used to avoid contamination caused by IgG’s heavy 
chain to achieve a better signal. The rest part of the Western blot protocol was 
standard as described in Chapter 2.4. 
After the whole IP procedure, TEAD1 could be detected in the precipitant 
of anti-RUNX3 antibody, indicating that TEAD1 and RUNX3 coexist in the 
same protein complex in HGC-27 cell (Fig 3.1). 
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Figure 3.1 TEAD1 and RUNX3 coexist in the same protein complex in HGC27 
cell line. TEAD1 was co-immunoprecipitated with RUNX3 in the precipitant of 
anti-RUNX3 antibody, indicating that TEAD1 and RUNX3 are in the same 
protein complex. 
 
3.3 The interaction between RUNX3 and TEADs is independent on YAP 
In the previous IP experiment, it was already shown that TEAD1 and 
RUNX3 coexist in the same protein complex. It might be YAP dependent since 
YAP was able to interact with both TEAD1 and RUNX3.  
It had been reported that RUNX3 interacted with YAP via its PY motif. By 
deleting the whole PY motif in RUNX3, the interaction between RUNX3 and 
YAP should be totally abolished. 
Here, a RUNX3 mutant in which the whole PY motif was deleted was used 
to perform co-IP with TEAD proteins in HEK293T cells to test whether 
RUNX3-TEAD interaction was mediated by YAP. 
 The result showed that the deletion of the whole PY motif in RUNX3 could 
abolish its interaction with YAP, while RUNX3’s binding with TEAD1/4 
largely remained intact (Fig 3.2). This result indicated that the interaction 
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between RUNX3 and TEAD proteins is not mediated by YAP. 
  
Figure 3.2 The interaction between RUNX3 and TEADs is independent on 
YAP. HEK293T Cell was transfected with pEGFPC2-YAPS127A, pcDNA-Flag-
RUNX3 or pcDNA-Flag-RUNX3ΔPY plasmids accordingly (1µg/10cm dish). 
Cells were harvested at 24 hours after transfection and IP was performed using 
M2-Flag agarose beads. ΔPY meant that the whole PY motif of RUNX3 was 
deleted in this construct. RUNX3ΔPY mutant failed to interact with YAP but it 
was still able to interact with TEAD1/4. 
 
3.4 The N-terminal sequence of RUNX3 is critical for its interaction with 
TEAD proteins 
The results described above showed that the interaction between RUNX3 
and TEAD proteins is independent on YAP, suggesting that RUNX3-TEAD 
interaction was a novel protein-protein interaction which deserved more 
investigation.  
RUNX3 is composed of many domains, including Runt domain, activation 
domain, inhibition domain as well as VWRPY motif. To identify which domain 
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was utilized for RUNX3’s interaction with TEAD proteins, IP using truncated 
RUNX3 was performed to compare their ability to interact with TEAD proteins. 
The structure of truncated RUNX3 construct is shown in Fig 3.3A. 
The IP result showed that the RUNX3-1-183 had strong interaction with 
TEAD1/4 while the RUNX3-182-415 had a significantly impaired binding to 
TEAD proteins, indicating that the sequence at the N-terminal of RUNX3 is 
critical for its interaction with TEAD proteins (Fig 3.3B). 
 As described in the diagram showing truncated RUNX3’s structure, the 
RUNX3-1-187 construct mainly contained the Runt domain (Fig 3.3A). So we 
hypothesised that RUNX3 might utilize the Runt domain to interact with TEAD 
proteins based on the result of this experiment. 
  




Figure 3.3 Exogenous IP using truncated forms of RUNX3 in HEK293T cell 
showed that the N-terminus of RUNX3 is important for the interaction between 
RUNX3 and TEAD proteins. (A) A diagram showing the structure of truncated 
RUNX3 constructs. (B) Exogenous IP result using truncated RUNX3 to pull 
down endogenous TEAD1/4. HEK293T cells were transfected with the 
truncated RUNX3 constructs (1μg/10cm dish) accordingly. Cells were harvested 
at 24 hours after transfection and IP was performed using M2-Flag agarose 
beads. The RUNX3-1-187 showed strong interaction with TEAD1/4 while 
RUNX3-182-415 showed significantly impaired binding to TEAD1/4. 
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3.5 Runt domain of RUNX3 interacts with TEAD1 directly in vitro 
Based on the results of previous experiments, we hypothesised that RUNX3 
might utilize the Runt domain (53-186 residues of RUNX3) to interact with 
TEAD proteins. To test this hypothesis, we designed this in vitro binding 
experiment using GST pull down method to check whether Runt domain alone 
was sufficient for RUNX3’s interaction with TEAD1 in vitro. 
In this experiment, Myc-TEAD1 protein was prepared using TnT® Quick 
Coupled Transcription/Translation System (Promega) as described in Chapter 
2.17. Recombinant GST protein and GST-Runt (53-186 residues of RUNX3) 
fusion protein were prepared using Rosetta™(DE3) cells and immobilized on 
GSH agarose beads as described in Chapter 2.15. The GST pull down 
experiment was performed by incubating GSH beads coated with GST or GST-
Runt fusion proteins with TEAD1 protein resuspended in IP buffer, as described 
in Chapter 2.16. 
The result of this GST pull down experiment showed that recombinant 
GST-Runt fusion protein alone was able to bind with TEAD1 protein in vitro, 
indicating that there is a direct interaction between Runt domain and TEAD1 
protein (Fig 3.4). 
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Figure 3.4 The direct protein-protein interaction between Runt domain and 
TEAD1 is shown by GST pull down experiment in vitro. GST, GST-Runt 
domain (53-186 residues of RUNX3) and full-length TEAD1 proteins were 
synthesized in vitro. GST and GST-Runt proteins were immobilized on GSH 
beads. GSH beads coated with GST-Runt protein were able to pull down 
TEAD1 protein in vitro. 
 
3.6 The residues 101-200 of TEAD4 are critical for its interaction with RUNX3 
In order to determine the binding domain of TEAD4 for interacting with 
RUNX3, IP experiments using TEAD4 mutants truncated from both N-terminus 
and C-terminus were carried out. 
In the first part of this experiment, exogenous IP was performed using 
TEAD4 mutants truncated from N-terminus, whose structures are shown in Fig 
3.5A. The result showed that deleting the first 100 residues of TEAD4 did not 
cause any obvious reduction for TEAD4-RUNX3 interaction, while deleting the 
first 200 residues of TEAD4 totally abolished TEAD4’s interaction with 
RUNX3 (Fig 3.5B). This result indicated that the 101-200 residues of TEAD4 
are crucial for the interaction between RUNX3 and TEAD4.  
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In the second part of this experiment, exogenous IP was performed using 
TEAD4 mutants truncated from C-terminus, whose structures are shown in Fig 
3.5C). The IP result showed that TEAD4’s first 100 residues alone were not able 
to interact with RUNX3, while the truncated TEAD4 which contains 1-200 
residues started binding with RUNX3, indicating that the 101-200 residues of 
TEAD4 play an important role for the interaction between RUNX3 and TEAD4 
(Fig 3.5D). 
Taken together, both experiments indicated that the 101-200 residues of 
TEAD4 play an important role for the interaction between RUNX3 and TEAD4. 
 
 
- 71 - 
 
Figure 3.5 TEAD4’s 101-200 residues are important for TEAD4-RUNX3 
interaction. (A) A diagram showing the structure of TEAD4 mutants truncated 
from N-terminus. (B) Exogenous IP result using TEAD4 mutants truncated from 
N-terminus. HEK293T cells were transfected with the RUNX3 construct 
(1μg/10cm dish) and truncated TEAD4’s constructs (1μg/10cm dish) 
accordingly. Cells were harvested at 24 hours after transfection and IP was 
performed using HA agarose beads.  TEAD4-101-434 was still able to interact 
with RUNX3, while TEAD4-201-434 failed to show any interaction with 
RUNX3. (C) A diagram showing the structure of TEAD4 mutants truncated 
from C-terminus. (D) Exogenous IP result using TEAD4 mutants truncated from 
N-terminus. HEK293T cell were transfected with the RUNX3 construct 
(1μg/10cm dish) and truncated TEAD4’s constructs (1μg/10cm dish) 
accordingly. Cells were harvested at 24 hours after transfection and IP was 
performed using HA agarose beads. TEAD4-1-100 did not show any interaction 
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with RUNX3, while TEAD4-1-200 and TEAD4-1-300 were able to pull down 
RUNX3. 
 
3.7 Residues 101-125 of TEAD4 are critical for its interaction with RUNX3 
Previous experiments showed that the 101-200 residues of TEAD4 were 
crucial for the interaction between RUNX3 and TEAD4. Aiming to identify a 
shorter key sequence required for this interaction, IP using TEAD4’s small 
deletion mutants was performed. 
As it was shown in the diagram, small deletions of 25 residues were 
introduced to TEAD4 from residue 101 to 200 sequentially (Fig 3.6A). 
According to the IP result, all the TEAD4’s small deletion mutants could be 
equally expressed except HA-TEAD4Δ126-150. In this experiment, HA-
TEAD4Δ101-200 was a negative control for RUNX3 binding according to the 
results of previous experiments.  
The deletion of TEAD4’s 101-125 residues could totally abolish its 
interaction with RUNX3, indicating that the 101-125 residues of TEAD4 are the 
shorter key sequence for RUNX3-TEAD4 interaction which we aimed to 
discover in this experiment (Fig 3.6B). 
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Figure 3.6 TEAD4’s residues 101-125 are critical for its interaction with 
RUNX3. (A) A diagram showing the structure of TEAD4’s small deletion 
mutants used in this experiment. (B) Exogenous IP using TEAD4’s small 
deletion mutants. HEK293T cells were transfected with the RUNX3 construct 
(1μg/10cm dish) and TEAD4’s small deletion mutants (1μg/10cm dish) 
accordingly. Cells were harvested at 24 hours after transfection and IP was 
performed using HA agarose beads. Deletion of residues 101-125 of TEAD4 
could totally abolish TEAD4’s interaction with RUNX3. TEAD4Δ101-200 
mutant was used as a negative control here. 
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3.8 RUNX3, TEAD4 and YAP can form a ternary complex in vitro 
Based on published data and the data generated in previous experiments by 
our own, it had been shown that RUNX3 can interact with YAP as well as 
TEAD4. Here, sequential IP was performed using RUNX3, YAP and TEAD4 
proteins to study whether these two interactions (RUNX3-YAP and RUNX3-
TEAD4) could coexist or be mutually exclusive to each other. 
The Flag-RUNX3, GFP-YAP and HA-TEAD4 proteins were prepared 
using TnT® Quick Coupled Transcription/Translation System (Promega) as 
described in Chapter 2.17. The proteins were mixed in IP buffer in vitro. 
Sequential IP was performed using M2-Flag agarose beads followed by GFP 
agarose beads, as described in Chapter 2.5 and illustrated in the figure below 
(Fig 3.7). According to the principle of sequential IP, if three proteins could 
coexist in the same complex, the TEAD4 protein should still be detectable in the 
precipitant after two rounds of immunoprecipitations with antibodies targeting 
YAP and RUNX3. Otherwise, it would indicate that RUNX3-TEAD interaction 
and RUNX3-YAP interaction are mutually exclusive to each other. 
The result of sequential IP showed that after two rounds of IP with 
antibodies targeting Flag-RUNX3 and GFP-YAP, the HA-TEAD4 was still 
detectable in the final IP products, indicating these three proteins, Flag-RUNX3, 
GFP-YAP and HA-TEAD4 can coexist within the same complex (Fig 3.8).  
  
- 75 - 
 
 
Figure 3.7 A diagram showing the work-flow of sequential IP using RUNX3, 
YAP and TEAD4 proteins. All protein complexes which contained RUNX3 
would be precipitated first, and they would be eluted mildly from the beads by 
peptide competition. Then the second round of IP was performed in this eluted 
mixture using an antibody targeting YAP. If three proteins could coexist in the 
same complex, the TEAD4 protein should still be detectable after these two 
rounds of precipitations. Otherwise, it indicated that RUNX3-TEAD interaction 
and RUNX3-YAP interaction are mutually exclusive. 
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Figure 3.8 Flag-RUNX3, GFP-YAP and HA-TEAD4 proteins coexist in the 
same complex. In this sequential IP experiment, all three proteins were 
synthesized in vitro and mixed in IP buffer. First round of IP was performed 
using M2-Flag agarose beads targeting Flag-YAP, the precipitants were eluted 
by incubating the beads with 3X Flag peptide. The second round of IP was 
performed using GFP agarose beads targeting GFP-RUNX3 in the eluted 
products. After two rounds of IP, HA-TEAD4 was still detectable in the second 
IP product. 
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3.9 The mutation at Leucine
121
 of RUNX3 can abolish its interaction with 
TEAD proteins 
RUNX3 is highly versatile, and its interaction with TEAD proteins might 
only represent a small part of its functions. For a better evaluation of the 
biological functions of RUNX3-TEAD interaction, a proper mutant RUNX3 
control should be used to prevent potential bias caused by other functions of 
RUNX3. The ideal mutant RUNX3 control should fulfill the following two 
requirements: first, it can not interact with TEAD proteins; second, it still retains 
other features of wild-type RUNX3.  
In this experiment, several RUNX3 mutants with point mutations in the 
Runt domain were tested by immunoprecipitation to see whether these 
mutations could abolish RUNX3’s interaction with TEAD proteins. RUNX3’s 
other functions including heterodimerization with CBFβ, the most important co-
factor which RUNX3 required for a stable DNA binding and its proper functions 
as a transcription factor, as well as RUNX3’s ability to trigger the transcription 
of its target genes, were tested via immunoprecipitation and dual-luciferase 
reporter assay. 
In the first immunoprecipitation experiment measuring RUNX3 mutants’ 
interaction with TEAD proteins, there were four Runt domain mutants showing 
weaker binding to TEAD proteins (Fig 3.9). Among them, RUNX3L121H mutant 
and RUNX3R122C mutant could not interact with TEAD proteins at all, while 
RUNX3R143Q and RUNX3G145E showed partially impaired binding with TEAD 
proteins. 
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 In the second immunoprecipitation experiment measuring CBFβ binding 
ability, RUNX3L121H  mutant exhibited similar binding to CBFβ, compared with 
wild-type RUNX3 (Fig 3.10). 
 The dual-luciferase reporter assay, which measured RUNX3’s ability to 
trigger the expression of downstream genes, showed that the mutation of  
Leucine
121
 to either Histidine or Proline did not reduce RUNX3’s ability to drive 
the expression of genes by P14 promtor or IgCα promoter (Fig 3.11). 
 Taken together, RUNX3L121H was chosen as the best mutant control for the 
future study about the biological functions of RUNX3-TEAD interaction, due to 
the fact that this mutation can totally abolish RUNX3’s binding with TEAD 
proteins while it still retains RUNX3’s basic functions to heterodimerize with 
CBFβ and to trigger the expression of downstream genes. 
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Figure 3.9 RUNX3L121H and RUNX3R122C can not interact with TEAD proteins, 
while RUNX3R143Q and RUNX3G145E show impaired binding with TEAD1/4. 
HEK293T cells were transfected with the RUNX3 mutants (1μg/10cm dish) 
accordingly. Cells were harvested at 24 hours after transfection and IP was 
performed using GFP agarose beads. The result showed that RUNX3L121H 
mutant and RUNX3R122C mutant could not interact with TEAD proteins at all, 
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Figure 3.10 RUNX3L121H mutant and wild-type RUNX3 exhibit similar binding 
to CBFβ. HEK293T cells were transfected with the RUNX3 constructs 
(1μg/10cm dish) accordingly. Cells were harvested at 24 hours after transfection 
and IP was performed using GFP agarose beads. The result showed that 
RUNX3L121H mutant and wild-type RUNX3 showed similar binding to CBFβ. 
 
 
Figure 3.11 The mutation of Leucine
121
 to either Histidine or Proline does not 
reduce RUNX3’s ability to drive the expression of genes triggered by p14 
promtor or IgCα promoter. HEK293T cells were transfected with reporter 
plasmids and RUNX3 mutant plasmids accordingly. The cells were harvested at 
24 hours after transfection. The promoter activity were determined by dual-
luciferase assay. 
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3.10 Summary and discussion 
In this chapter, the endogenous IP using RUNX3 antibody showed that 
TEAD1 and RUNX3 coexisted in the same protein complex (Fig 3.1). Then 
RUNX3-TEAD’s co-IP experiment using RUNX3 mutants lacking YAP 
binding ability was employed to show that TEAD-RUNX3 interaction was a 
novel protein-protein interaction which was independent on YAP-RUNX3 
interaction (Fig 3.2). Mapping experiments using both truncated mutants as well 
as purified proteins showed that the Runt domain of RUNX3 as well as residues 
101-125 of TEAD4 were crucial for TEAD4-RUNX3 interaction (Fig 3.3 - 3.6).  
 TEA domain is responsible for TEAD proteins’ recognition and binding of 
consensus sequence, which is crucial for the transcriptional function of TEAD 
proteins. The structure of TEA domain has already been solved (Anbanandam et 
al, 2006). It is a three-helix bundle with a homeodomain fold (Fig 3.12A). For 
TEAD4, residues 47-57, residues 78-88 and residues 97-109 form three helixes, 
among which the third one is the DNA-recognition helix (Anbanandam et al, 
2006). The sequence of the DNA-recognition helix and the key sequence 
required for TEAD4-RUNX3 interaction are compared in Fig 3.12B. 
Interestingly, a considerate portion of this helix (residues 97-109) locates within 
the key sequence (residues 101-125) which TEAD4 requires for its interaction 
with RUNX3, suggesting that RUNX3 might have an influence on the DNA 
binding of TEAD4. This hypothesis would be further explored in the next 
chapter.  
 RUNX3’s Runt domain is a highly versatile domain, which is responsible 
for binding with DNA, heterodimerizing with CBFβ and interacting with 
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multiple partners like Bmi-1 (B lymphoma Mo-MLV insertion region 1 
homolog), GATA-1 (GATA-binding factor 1) and LEF-1 (Lymphoid enhancer-
binding factor-1) (Elagib et al, 2003; Howcroft et al, 2005; Yu et al, 2012b). The 
structure of Runt domain (RUNX1, residues 50-183) has already been solved 
(Ito, 2004; Nagata & Werner, 2001; Warren et al, 2000). It forms a 12-tranded 
(10 antiparallel and two parallel strands) β-barrel that adopts an s-type 





 are critical for RUNX3-TEAD interaction, whose 




 in RUNX1. Both of 
these residues localize in the Runt domain’s loop βC-D, which has not been 
implicated in DNA binding. This loop makes a number of contacts with CBFβ 
through the side chain of Tyrosine
113
, while the rest amino acid residues are 
available for making interactions with other proteins (Nagata & Werner, 2001; 
Warren et al, 2000). 
 According to the sequential IP result, RUNX3, TEAD4 and YAP could 
coexist in the same complex. The schematic diagram below is a summary of all 
possible interactions among these three proteins (Fig 3.14). RUNX3 and YAP 
interact through PY motif of RUNX3 and WW domain of YAP. RUNX3 and 
TEAD4 interact through Runt domain of RUNX3 and residues 101-125 of 
TEAD4. The C-terminal sequence of TEAD4 interacts with YAP at the TEAD 
binding domain which is located at the N-terminal of YAP. Even though it is 
shown here that three proteins can form stable ternary complex, more 
complicated regulation might exist to modulate the binding preference of each 
protein in different biological contexts. 
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 RUNX3’s ability of binding to TEAD-YAP complex instead of TEAD 
alone is important, due to the fact that TEAD-YAP complex is the 
transcriptionally active form which is able to drive the expression of target 
genes promoting proliferation and metastasis, while TEAD proteins alone do not 
have any intrinsic transcription activation domain (Jiang & Eberhardt, 1996; 
Xiao et al, 1991). RUNX3’s role in this ternary complex would be further 
explored in the next chapters. 
 The study of TEAD proteins’ partners has been going on for decades, and 
several proteins have been found to be interacting with TEAD. For example, 
myc-associated factor X (Max) interacts with TEAD1 to trigger the expression 
of cardiac alpha-myosin heavy-chain (α-HMC) gene (Gupta et al, 1997). The 
steroid receptor co-activator-1 (SRC-1) is also able to increase the 
transcriptional activity of TEAD2 by 2-3 folds (Belandia & Parker, 2000). On 
the other hand, TATA-binding Protein (TBP) binds to TEAD1 to repress 
chorionic somatomammotropin (hCS) promoter activity in choriocarcinoma 
(BeWo) cells (Jiang & Eberhardt, 1996). Till the discovery of YAP, there has 
always been an argument about TEAD’s co-activator which could universally 
and robustly trigger the transcriptional activity of TEAD proteins (Vassilev et al, 
2001).  
 TAZ is homologous to YAP and shares many functional similarities with 
YAP. TAZ heterodimerizes with TEAD proteins in a similar manner with YAP, 
and it also contains conserved WW domain (Mahoney et al, 2005). Our finding 
about RUNX3’s interaction with TEAD-YAP complex should also be applicable 
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for TEAD-TAZ complex, even though no experiments have been performed to 
prove it. 
 These days, a new pursuit looking for the repressor for TEAD-YAP 
complex has begun. Recently, vestigial-like family member 4 (Vgll4) is 
discovered to antagonize YAP by competitively binding to TEAD in a similar 
manner with TEAD-YAP interaction (Jiao et al, 2014; Zhang et al, 2014). This 
discovery offers us a new understanding of how TEAD-YAP activity is 
regulated in cell nucleus. Like Vgll4, RUNX3 is also a nuclear protein. It would 
be interesting to test whether RUNX3-TEAD interaction also plays a regulatory 
role for TEAD-YAP activity. 
  
Figure 3.12 Structure of TEA domain. (A) Solution NMR structure of TEA 
domain. Ribbon diagram shows front view of TEA domain’s fold in which 
helices H1 and H2 pack against H3. N and C termini are labelled (Anbanandam 
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et al, 2006). (B) The sequence of the TEAD4’s DNA-recognition helix and the 
key sequence required for TEAD4-RUNX3 interaction.  
Figure 3.13 Solution NMR structure of Runt domain (cyan) and CBFβ 
(magenta), viewed perpendicular to the long axis of CBFβ. The concave surface 
of the Runt domain β-sheet, formed strands βG, βF and βC, packs against the 
complementary convex strand β3 of CBFβ (Warren et al, 2000).  
 
 
Figure 3.14 A diagram showing all possible interactions among RUNX3, 
TEAD4 and YAP. RUNX3 interacts with TEAD4 through Runt domain at the 
N-terminus, while interacting with YAP via the PY motif at the C-terminus, 
forming a ternary complex.  






RUNX3 negatively regulates TEAD proteins’ 
transcriptional activity by direct protein-
protein interaction 
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4.1 Introduction 
 In the previous chapter, the novel protein-protein interaction between 
RUNX3 and TEAD proteins was discovered. However, the consequence of this 
interaction still remained unknown. 
 In broad terms, RUNX3 tends to reduce cell growth by various mechanisms 
and TEAD proteins can trigger the expression of genes promoting cell 
proliferation as well as migration. It seems that RUNX3 and TEAD proteins 
play opposite roles for cell growth, which suggests that RUNX3 might inhibit 
the function of TEAD proteins. 
 Here, to test the hypothesis that RUNX3 could inhibit the transcriptional 
activity of TEAD proteins, a series of experiments were designed, including 
luciferase reporter assay, EMSA and transcription factor enrichment assay. In 
the last part of previous chapter, the RUNX3L121H mutant was identified as an 
ideal mutant lacking the ability to interact with TEAD proteins while retaining 
other major functions of RUNX3, which would be widely used in this chapter. 
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4.2 RUNX3 can reduce the transcriptional activity of TEAD-YAP complex 
A TEAD luciferase reporter plasmid containing eight TEAD binding boxes 
can be used to measure the transcriptional activity of TEAD proteins in cells by 
measuring the intensity of light generated by the luciferase enzyme whose 
expression is driven by TEAD proteins (Fig 4.1A). Here, this reporter plasmid 
was used to test whether RUNX3 had any influence on the transcriptional 
activity of TEAD. 
According to the result of dual-luciferase reporter assay in which RUNX3 
was overexpressed in HEK293T cells at increasing doses, wild-type RUNX3 
could reduce the transcriptional activity of TEAD4 at a dose dependent manner, 
while RUNX3L121H (RUNX3 mutant which could not interact with TEAD 
proteins) could not, indicating that RUNX3’s inhibitory effect on the 
transcriptional activity of TEAD4 is highly dependent on RUNX3’s direct 
interaction with TEAD4 (Fig 4.1B, C). 
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Figure 4.1 RUNX3 reduces the transcriptional activity of TEAD-YAP complex. 
(A) Schematic representation of TEAD luciferase reporter with 8 TEAD binding 
boxes in pGL3 vector. (B) Dual-luciferase reporter assay measuring TEAD’s 
transcriptional activity after overexpressing wild-type RUNX3 or RUNX3L121H 
mutant at increasing doses in HEK293T. Wild-type RUNX3 could reduce the 
transcriptional activity of TEAD4 at a dose dependent manner, while 
RUNX3L121H could not. (C) Western blot result of cell lysates from dual-
luciferase reporter assay measuring TEAD’s transcriptional activity after 
overexpressing wild-type RUNX3 or RUNX3L121H mutant. 
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4.3 Overexpression of RUNX3 does not have any negative effect on the 
interaction between TEAD and YAP 
In previous experiments, it had already been shown that RUNX3 could 
reduce the transcriptional activity of TEAD4 at a dose dependent manner. Since 
the transcriptional activity of TEAD proteins was highly dependent on its 
binding with its co-activator YAP, it was worthy to study whether RUNX3 
could impair the binding between TEAD and YAP. The interaction between 
TEAD and YAP could be evaluated using immunoprecipitation method. 
According to the result of TEAD-YAPS127A co-immunoprecipitation assay 
in which RUNX3 was overexpressed at different doses, the interaction between 
YAPS127A and TEAD4 did not show any significant reduction, indicating that 
RUNX3 does not interrupt YAP-TEAD interaction (Fig 4.2 A, B). This result 
suggested that RUNX3 reduces the transcriptional activity of TEAD by other 
means. 




Figure 4.2 RUNX3 overexpression does not interrupt the interaction between 
TEAD and YAPS127A. (A)Western blot result of TEAD-YAPS127A co-
immunoprecipitation assay in which RUNX3 was overexpressed at different 
doses. HEK293T cells were transfected with the pBABE-HA-TEAD4 
(1µg/10cm dish), pCDNA-Flag-YAPS127A (1µg/10cm dish) and pEGFP-C1-
RUNX3 (0, 0.5, 1.5, 3, 6 µg/10cm dish) accordingly. Cells were harvested at 24 
hours after transfection and IP was performed using M2-Flag agarose beads. 
The IP result showed that TEAD4 could be equally pulled down by YAPS127A 
while the overexpression doses of RUNX3 increased. (B) Band intensity 
quatification for the Western blot result. The ratio between precipitated 
YAPS127A and TEAD4, which reflected the binding between YAPS127A and 
TEAD4, did not show any significant reduction as the doses of RUNX3 
overexpression increased. 
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4.4 RUNX3 can reduce the TEAD4-1-125’s interaction with DNA in vitro 
EMSA (Electrophoretic mobility shift assay) is a traditional method to 
study the binding between proteins and DNA in vitro. Here, we utilized this 
method to study whether RUNX3 could affect the binding between TEAD4-1-
125 (containing the DNA recognition helix of TEAD4) and the consensus 
sequence of DNA which TEAD proteins usually recognized. 
GST-HA-TEAD4-1-125 protein was purified using E.Coli and GSH beads 
as described previously in Chapter 2.15. HA-TEAD4-1-125 was cleaved from 
GSH beads by Thrombin digestion (0.1U/ml) for 1 hour at room temperature. 
Flag-RUNX3 protein was expressed in HEK293T and precipitated using M2-
Flag beads as described in chapter 2.5. Then RUNX3 protein was eluted from 
the beads by incubating with 3XFlag peptide (500 µg/ml) at 4 °C for 1 hour. 
EMSA was performed using LightShift Chemiluminescent EMSA Kit (Thermo) 
as described in Chapter 2.8. 
 According to the result of EMSA experiment, the shifted band could be 
super-shifted by the adding of HA antibody, ensuring that this band shift was 
caused by the binding of HA-TEAD4-1-125 (as shown in the first lane of Fig 
4.3). When high doses of RUNX3 was added to the reaction mix, the shift band 
became weaker and finally disappeared, indicating that RUNX3 could reduce 
the DNA binding ability of TEAD proteins. This phenomenon was not observed 
at low dose of RUNX3, which might be due to the amount of RUNX3 protein 
was not high enough to generate any obvious competition effects (Fig 4.3). 
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Figure 4.3 RUNX3 could reduce the binding between TEAD4-1-125 and TEAD 
probe. The band shift was caused by the binding of HA-TEAD4-1-125. 
Increasing doses of purified RUNX3 were added to the EMSA reaction mix. 
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4.5 RUNX3 reduces TEAD1’s interaction with DNA in vitro 
Transcription factor enrichment assay is an alternative way to evaluate the 
binding between DNA and transcription factors. In this assay, the synthesized 
DNA probe is immobilized on beads and incubated with cell lysis, so all the 
proteins which can bind to this probe will be precipitated together with the beads 
and they can be analyzed by techniques like Western blot and silver staining.  
Here we performed this transcription factor enrichment assay to study 
whether RUNX3 could reduce the DNA binding ability of endogenous TEAD1. 
In this experiment, HEK293T cells were transfected with RUNX3 or RUNX1 
plasmids, and nuclear fraction was extracted and incubated with beads coated 
with synthesized TEAD probe or mutated TEAD probe. The precipitants were 
analysis by Western blot to measure the amount of endogenous TEAD1 which 
could bind to the TEAD probes. 
According to the result of this experiment, wild-type RUNX3 significantly 
reduced the amount of TEAD1 protein which bound to the TEAD probe, while 
RUNX3L121H mutant could not achieve this (Fig 4.4). This observation showed 
that RUNX3 reduces the endogenous TEAD1-DNA interaction, supporting the 
conclusion we obtained from the previous EMSA experiment, which was done 
using recombinant TEAD4-1-125 protein. Similar results could be obtained 
using RUNX1 constructs (Leucine
117
 of RUNX1 is conserved to Leucine
121
 of 
RUNX3), since the Runt domain is highly conserved between RUNX1 and 
RUNX3. This result was predicted and it suggested that RUNX1 can also 
disrupt the interaction between TEAD1 and DNA. 
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Figure 4.4 RUNX3 reduces the endogenous TEAD1-DNA interaction. 
HEK293T cells were transfected with RUNX3 or RUNX1 plasmids (1µg/6cm 
dish), and nuclear fraction was extracted and incubated with beads coated with 
synthesized TEAD probe or mutated TEAD probe. The precipitants were 
analyzed by Western blot to measure the amount of endogenous TEAD1 
proteins which bound to TEAD probe. Western blot result showed that wild-
type RUNX3 and RUNX1 could reduce the DNA binding ability of TEAD1, 
while RUNX3L121H or RUNX1L171H mutants could not achieve this. 
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4.6 Summary and discussion  
 In this chapter, the dual-luciferase reporter assay using TEAD reporter 
showed that RUNX3 reduced the transcription activity of TEAD4 (Fig 4.1). 
However, the in vitro competition assay showed that the protein-protein 
interaction between TEAD4 and YAP remained intact (Fig 4.2). In contrast, 
both EMSA experiment and transcription factor enrichment assay showed that 
RUNX3 reduced the DNA binding ability of TEAD proteins (Fig 4.3, 4.4). 
 All these observations led to the final conclusion that RUNX3 can impair 
the DNA binding ability of TEAD4 by direct protein-protein interaction which 
masks the DNA binding surface of TEAD4, and reduce the transcriptional 
activity of TEAD4. 
 Protein-protein interaction is an important part for the regulation of 
transcription. Even though the majority of transcription factors are initially 
characterized as a stimulating factor for gene expression, more and more 
evidence shows that inhibitory transcription factors play an equally important 
role in the regulation of gene expression (Harrison, 1991). There are several 
ways for the inhibitory transcription factors to suppress an activating factor: (1) 
interfering with the DNA binding of activating factors by reorganising the 
chromatin structure, masking the binding site, or forming a protein-protein 
complex that does not bind to DNA (Hagen et al, 1994; Yang-Yen et al, 1990; 
Zink & Paro, 1995); (2) quenching the transcription activation by competing 
with transcription co-activators (Wagner & Green, 1991). Obviously, our 
finding about RUNX3’s regulation on TEAD activity belongs to the first 
category, while the VGLL4, which interrupts TEAD-YAP interaction by 
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occupying YAP binding domain of TEAD proteins, belongs to the second 
category (Jiao et al, 2014; Zhang et al, 2014). The comparison between RUNX3 
and VGLL4 is summarized in Fig 4.5. 
 RUNX3 is a highly versatile transcription factor, which is able to activate or 
suppress the expression of target genes in different biological contexts (Wheeler 
et al, 2002). Furthermore, RUNX3 can suppress gene expression in multiple 
ways. For example, RUNX3 is able to bind to SUV39H1 (Histone-lysine N-
methyltransferase SUV39H1), which can recruit histone methyltransferases, 
contributing to the silencing of target genes including CD4 (cluster of 
differentiation 4), VEGF (Vascular Endothelial Growth Factor) and AKT1 (v-akt 
murine thymoma viral oncogene homolog 1) (Lin et al, 2012; Peng et al, 2006; 
Reed-Inderbitzin et al, 2006). RUNX3 is also able to associate with other 
transcription factors, forming complexes which have a lower DNA binding 
ability. For example, RUNX3 forms a ternary complex with β-catenin/TCF4 and 
attenuates Wnt signaling activity in intestinal epithelial cells (Ito et al, 2008). In 
The CD4
+
 helper T cells, RUNX3 interacts with GATA3 and attenuates GATA3 
transcriptional activity (Kohu et al, 2009). Our novel finding about the 
interaction between RUNX3 and TEAD proteins adds another example to this 
category. 
 Recently, RUNX3 was found to be able to physically interact with SAV1, 
and to form close association with MST2, leading to a higher activity of 
MST2/SAV1 to cause cell death (Min et al, 2012). This report mainly 
emphasized the role of RUNX3 in the upstream Hippo pathway, while our 
research mainly focused on RUNX3’s influence on the effecters of Hippo 
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pathway. The EMSA experiment and the transcription factor enrichment 
experiment which we performed directly studied the DNA binding ability of 
TEAD proteins, without any bias from upstream signals of Hippo pathway. 
However, both upstream and downstream studies point to the same endpoint that 
RUNX3 can negatively regulate TEAD-YAP activity, indicating that RUNX3 is 
indeed having an important role in the regulation of TEAD-YAP activity at 
multiple levels. 
 Currently, our understanding about the regulation of TEAD-YAP activity is 
mainly focused on the localization of YAP. Hippo pathway, angiomotin and 
ZO-2 all negatively regulate the transcriptional activity of TEAD by confining 
YAP in cytoplasm either by physical interaction with YAP or phosphorylating 
YAP (Zhao et al, 2010a). One exception is VGLL4, which blocks TEAD-YAP 
interaction by occupying YAP binding domain in TEAD proteins (Jiao et al, 
2014; Zhang et al, 2014) (Fig 4.5). Considering the vital role of TEAD-YAP 
complex in maintaining a proper homeostasis for metazoan, its regulation must 
be multilayered and error-proofing. The discovery of VGLL4’s role filled a 
vacancy in our understanding of TEDA-YAP’s regulation within cell nucleus. 
Now our discovery about RUNX3’s role in blocking TEAD’s binding to DNA 
reveals an alternative way of suppressing TEAD-YAP activity within cell 
nucleus, complementary to VGLL4. 
 According to our new understanding about the regulation of TEAD-YAP 
complex, there are three layers of regulations for an error-proofing control of 
TEAD-YAP activity: (1) restricting YAP’s nuclear localization by multiple 
pathways; (2) altering the physical interaction between TEAD and YAP by 
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changing the amount of competitor for YAP; (3) limiting the DNA binding 
ability of TEAD proteins by RUNX3 (Fig 4.6). These three layers of regulations 
vigorously control the activity of TEAD-YAP complex at an extremely low 
level in the quiescent cells in adult tissues, whose malfunction is closely 
correlated with the development of cancer (Zhao et al, 2010a). The correlation 
between loss of Hippo pathway or VGLL4 expression with human cancers has 
already been discussed in Chapter 1.4.3, and RUNX3-TEAD interaction’s role 
in gastric cancer would be discussed in the next chapter. 
 
 
Figure 4.5 A comparison between RUNX3’s and VGLL4’s mechanisms of 
restricting TEAD-YAP activities. RUNX3 blocks TEAD proteins from binding 
to DNA, while VGLL4 blocks TEAD-YAP interaction by occupying YAP 
binding domain in TEAD proteins. 





Figure 4.6 A summary of pathways and proteins regulating TEAD-YAP activity.  





Chapter 5  
The biological significance of RUNX3-TEAD 
interaction in gastric cancer 
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5.1 Introduction 
 Based on previous two chapters, RUNX3 can suppress the transcriptional 
activity of TEAD-YAP complex by preventing TEAD proteins from binding to 
DNA. This might be one of the novel mechanisms explaining how RUNX3 
functions as a tumour suppressor, whose inactivation is frequently observed in 
gastric cancer. 
 In this chapter, the role of TEAD-YAP complex in gastric cancer would be 
examined first, since there were few reports studying this when we started this 
project in 2012. After we confirmed that TEAD-YAP complex was oncogenic in 
gastric epithelial cells, a series of experiments would be performed to test 
whether RUNX3 could inhibit the oncogenic activity of TEAD-YAP complex in 
the context of gastric cancer. 
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5.2 Knock down of TEAD or YAP causes growth retardation in a large 
portion of gastric cancer cell lines 
 TEAD-YAP complex has been shown to exhibit strong oncogenic activity 
in epithelial cells in various organs like liver, breast and colon (Zhao et al, 
2010a). Recently, YAP’s oncogenic role has been reported in stomach (Jiao et al, 
2014; Lim et al, 2014). However, the mechanism by which TEAD-YAP 
complex is involved in gastric carcinogenesis is poorly understood. Since gastric 
cancer cells are highly heterogeneous (Ji et al, 2002), a comprehensive study on 
the role of TEAD and YAP in gastric carcinogenesis would be necessary. 
 We performed stable knock down of TEAD1/3/4 in 13 gastric cancer cell 
lines, by using a retrovirus carrying shRNA targeting TEAD1/3/4. Cell growth 
was monitored using WST-1 assay as described in Chapter 2.13. The relative 
cell viability was determined by calculating the ratio between the growth rate of 
cells carrying shTEAD1/3/4 and the growth rate of cells carrying shScramble. 
 At the same time, Western blot analysis was also performed using cell lysis 
extracted from these cell lines, and the expression levels of YAP, TEAD1, 
TEAD3 and TEAD4 were determined by measuring the band intensity. The 
bands’ intensity was quantificated and the YAP-TEAD1/3/4 index was 
calculated as the sum of band intensity of YAP and TEAD1/3/4, normalized to 
the band intensity of GAPDH. 
 To validate our observations generated from stable knock down of TEAD 
proteins using shTEAD1/3/4, transient knock down of YAP and TEAD1 was 
also performed in 5 gastric cancer cell lines (MKN74, MKN28, AGS, HGC-27 
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and HS746T), and similar cell growth analysis was performed after these cells 
were treated with esiRNA targeting YAP and TEAD1.  
 According to the results of cell growth analysis, 8 out of 13 gastric cancer 
cell lines (MKN74, MKN28, YCC1, AGS NUG-C3, SCH, AZ521 and NCI-N87) 
showed significant growth reduction after TEAD1/3/4’s knock down, while the 
other 5 cell lines (YCC6, NUG-C4, MKN45, HGC-27 and HS746T) only 
exhibited minor response to the knock down (Fig 5.1A, D).  
 Similar observation could be achieved by transient knock down of TEAD1 
using esiRNA. MKN74, MKN28 and AGS responded more clearly to TEAD1 
knock down, compared with HGC-27 and HS746T (Fig 5.2A, B). Interestingly, 
knock down of YAP did not lead to exactly the same cell response compared 
with knock down of TEAD1. esiYAP caused a milder growth reduction than 
esiTEAD1 in MKN74, but it caused a much stronger growth reduction than 
esiTEAD1 in HS746T. In the rest of the three cell lines (MKN28, AGS and 
HGC-27), esiYAP and esiTEAD1 led to similar cell growth reduction (Fig 5.2A, 
B). 
 The Western blot analysis showed that most cell lines which responded well 
to TEAD’s knock down had a relatively higher expression level of YAP and 
TEAD proteins, as indicated in the quantification figure of YAP-TEAD1/3/4 
index (Fig 5.1B, C). 
 In summary, gastric cancer cell lines showed heterogenous responses to the 
stable knock down of TEAD1/3/4 as well as the transient knock down of YAP 
and TEAD1. Cell lines with high YAP and TEADs’ expression tended to exhibit 
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significant growth inhibition with shTEAD1/3/4, while cell lines with low YAP 
and TEADs’ expression did not respond appreciably to shTEAD1/3/4. 
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Figure 5.1 Knock down of TEAD1/3/4 causes growth retardation in a large 
portion of gastric cancer cell lines. (A) Cell growth analysis using WST-1 assay. 
The relative cell viability was determined by calculating the ratio between the 
growth rate of cells carrying shTEAD1/3/4 and the growth rate of cells carrying 
shScramble. (B) Western blot result of cell lysis extracted from gastric cancer 
cell lines. (C) The band intensity was quantificated and the YAP-TEAD1/3/4 
index was calculated as the sum of band intensity of YAP and TEAD1/3/4, 
normalized to the band intensity of GAPDH. (D) Western blot result showing 
the knocking down efficiency of shTEAD1/3/4 in MKN28 and AGS cell lines.  
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Figure 5.2 Knock down of YAP or TEAD1 by esiRNA reduces cell growth in 
gastric cancer cell lines. (A) Cell growth analysis using WST-1 assay. Cell lines 
were transfected with esiRNA accordingly, and seeded into 96-well plate for 
cell proliferation assay for 5 days. (B) Western blot results showing the 
knocking down efficiency in these cell lines.  
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5.3 YAP and TEAD1 are frequently overexpressed in gastric cancer specimen 
 IHC (Immunohistochemistry) is a standard method to study the protein 
expression in fixed tissues of clinical specimens. YAP has been reported to be 
overexpressed in many cancers, including liver, breast and colon cancers. YAP 
overexpression would directly lead to an enhanced transcriptional activity of 
TEAD proteins. Here, we performed IHC staining using YAP and TEAD1 
antibodies to obtain expression levels as well as expression patterns of YAP and 
TEAD1 in gastric cancer samples. 
 50 pairs of gastric cancer specimens and matched normal gastric tissues 
were stained using YAP and TEAD1 antibodies as described in Chapter 2.6. The 
overall clinical information was summarized in the chart below (Tab 5.1).  
 The result of IHC experiment revealed that YAP could only be weakly 
stained in a small portion of normal gastric tissues, while YAP staining was 
extraordinarily strong in gastric cancer tissues. Overexpressed YAP was 
localized in both cytoplasms as well as cell nucleus (Fig 5.3A). The IHC scoring 
was performed for YAP staining, and the result of Student T-test showed that 
the expression of YAP was significantly up-regulated in gastric cancer tissues 
compared with adjacent normal stomach tissues (Fig 5.3B). 
 TEAD1 was ubiquitously expressed in the cell nucleus of most epithelial 
cells in both normal and cancer tissues. The signal was slightly stronger in 
gastric cancer tissues than normal tissues, but the difference was not significant 
(Fig 5.3A). 
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 variables number of cases 
age (years) <=65 19 
>65 31 
sex male 32 
female 18 
tumour size (mm) <=50 28 
>50 21 






lauren classify diffuse 16 
intestinal 26 
 
Table 5.1 Summary of clinical information for patients offering gastric cancer 
specimen. 
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Figure 5.3 YAP and TEAD1 expressions are frequently up-regulated in gastric 
cancer, compared with adjacent normal stomach tissues. (A) Representative IHC 
staining results using YAP and TEAD1 antibodies in gastric cancer specimen or 
adjacent normal stomach tissues. (B) The student T-test result comparing the 
scoring results of YAP IHC staining intensity in both gastric cancer tissues and 
adjacent normal stomach tissues. 
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5.4 Higher YAP-TEAD mRNA expression is significantly correlated with 
poorer prognosis of gastric cancer patients 
 Higher mRNA expression of YAP and TEAD proteins would lead to an 
enhanced transcriptional activity of TEAD, which might have a negative 
influence on the prognosis of patients. Here we wanted to test this hypothesis by 
study whether the overall survival time was shorter for gastric cancer patients 
with higher TEAD-YAP expression. 
 Primary gastric cancer (GC) samples (n = 200) profiled on Affymetrix 
Human Genome U133 Plus 2.0 Genechip arrays (GSE15459) were preprocessed 
in a standard manner. After preprocessing, 185 GC samples were available for 
downstream analyses. GC samples were clustered using a K-medoids approach 
and Kaplan-Meier survival analysis, with overall survival as the outcome metric, 
was employed to compare GCs with “high” TEAD (TEAD1, TEAD2, TEAD3, 
TEAD4) and YAP gene expression to GCs with “low” expression of these genes. 
The log-rank test was used to assess the significance of the Kaplan-Meier 
analysis. Univariate and multivariate analyses were performed using Cox 
regression. 
 According to the result of clustering, 185 gastric cancer patients were 
clearly grouped into two groups according to the mRNA level of YAP, TEAD1, 
TEAD2, TEAD3, and TEAD4 (Fig 5.4A). Patients with higher TEAD-YAP 
expression (134 patients) showed significantly shorter overall survival time 
compared with patients with lower TEAD-YAP expression (51 patients), after 
adjusting for age, stage and tumour site (Fig 5.4B). 
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Figure 5.4 Higher YAP-TEAD mRNA expression is significantly correlated 
with poorer prognosis of gastric cancer patients. (A) Silhouette plot of micro 
array data set showed that all patients were divided into two groups according to 
the expression of YAP, TEAD1, TEAD2, TEAD3 and TEAD4. (B) Kaplan-
Meier survival analysis of gastric cancer patients with different TEAD-YAP 
expression levels. The log-rank test was used to assess the significance of the 
Kaplan-Meier analysis. Cox regression was used to adjust for age, stage and 
tumour site.    
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5.5 The expression levels of both RUNX1 and RUNX3 show significant 
reduction in gastric cancer patients with higher YAP-TEAD expression 
 Here we examined whether the expression level of RUNX1/3 and TEAD-
YAP expression levels were correlated, which could offer some clues indicating 
whether RUNX1/3 and TEAD-YAP were functionally related. 
 The same micro array cohort of Chapter 5.4 was used to investigate the 
expression levels of RUNX1 and RUNX3. Weights were first computed for 
each sample using expression of PTPRC (Protein Tyrosine phosphatise receptor 
type C, CD45), which was a measure of lymphocyte contamination within the 
tissue. Weight (W) per sample was computed using the formula: W = 1/ 
(PTPRCi/PTPRCmedian), where PTPRCi is the expression level of PTPRC in i
th
 
sample and PTPRCmedian is the median expression of PTPRC across all samples. 
The weighted RUNX gene expression was then computed multiplying the 
weight and RUNX expression for the each sample. A Welch two-sample t-test 
was employed to calculate the significance of a difference between RUNX 
expressions in “high” versus “low” TEAD-YAP expressors. All two-sided p-
values were reported. P < 0.05 was taken to be significant. 
 According to the result of statistical analysis, the expression levels of both 
RUNX1 and RUNX3 were significantly lower in gastric cancer patients with 
higher TEAD-YAP expression, indicating that RUNX3 inactivation might be 
functionally correlated with enhanced TEAD-YAP activity (Fig 5.5). 
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Figure 5.5 The expressions of both RUNX1 and RUNX3 show significant 
reduction in gastric cancer patients with higher YAP-TEAD expression. 
RUNX1 and RUNX3 expression was adjusted to PTPRC (CD45) expression 
level. A Welch two-sample t-test was employed to calculate significance of a 
difference between RUNX expressions in “high” versus “low” TEAD-YAP 
expressors. 
 
5.6 A large portion of potential TEAD-YAP target genes in gastric cancer 
specimen can be suppressed by RUNX3 in SNU16 gastric cancer cell line 
 Results described in chapter 4 indicated that RUNX3 can reduce the 
transcriptional activity of TEAD proteins. For a better understanding of which 
TEAD target genes were under such regulation of RUNX3, we used a series of 
bio-informatics analysis to compare microarray data from multiple resources, 
including the micro array performed in MCF10A cell line after YAP 
overexpression (Zhao et al, 2008), microarray performed using gastric cancer 
specimen, and microarray performed in SNU16 gastric cancer cell line after 
RUNX3 knocking down, aiming to identify a group of TEAD-YAP target genes 
which could be inhibited by RUNX3 in gastric cancer cell. This bioinformatic 
analysis consisted of two major steps, as described in details below. 
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 Step 1: Identify candidate TEAD-YAP target genes which are significantly 
up-regulated in gastric cancer specimens with high TEAD-YAP expression. 
 The gene expression signature promoted by YAP was previously 
established In MCF10A mammary epithelial cells. Using this published results, 
we reanalyzed gene expression data from cDNA microarray analyses which 
were performed on 185 gastric cancer tissues (GSE15459). This identified 187 
candidate TEAD-YAP target genes in gastric cancer specimens that met the 
following two criteria: 1) significantly up-regulated by YAP and YAP5SA, but 
not by TEAD-interaction mutant YAPS94A in MCF10A; 2) Significantly 
overexpressed in gastric cancer patients with high TEAD-YAP expression (Fig 
5.6A). 
 Step 2: Identify candidate TEAD-YAP target genes which can be inhibited 
by RUNX3 in SNU 16 gastric cancer cell line. 
 To perform microarray using SNU16 cell line, Controls (n = 3) and 
RUNX3-Knockdown (n = 3) samples were profiled on Illumina Human Ref-8 
arrays. Genes which were up-regulated in RUNX3-Knockdown samples were 
used to intersect with genes identified previously to be up-regulated in “TEAD-
YAP” high vs low expressors. The expression data from intersected genes were 
next subjected to hierarchical cluster analysis with average correlation as the 
distance measure. 
 According to the result of these bioinfomatics analysis, among the 187 
candidate gastric TEAD-YAP targets, 69 genes (36.7%) were up-regulated in 
SNU16 cell lines when RUNX3 was knocked down, indicating that a large 
portion of TEAD-YAP target genes were under the suppression of RUNX3 
- 116 - 
 
when RUNX3 was expressed at a physiological level. CTGF (connective tissue 
growth factor) was one of the most significantly induced TEAD-YAP target 
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Figure 5.6 A large portion of potential TEAD-YAP target genes in gastric 
cancer specimens are suppressed by RUNX3 in SNU16 gastric cancer cell line. 
(A) The strategy for identifying candidate TEAD-YAP target genes in gastric 
cancer specimens. (B) The candidate TEAD-YAP target genes set whose 
expression got up-regulated after RUNX3 knocking down in SNU16 cell line. 
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5.7 CTGF is negatively regulated by RUNX3 in gastric cancer cell lines 
 CTGF (connective tissue growth factor) is highlighted in the previous 
bioinformatic analysis as one of candidate gastric YAP-TEAD target genes 
which could be suppressed by RUNX3 in SUN16 gastric cancer cell line. At the 
same time, CTGF is a well-established TEAD-YAP target gene whose detailed 
mechanism by which it is regulated by TEAD-YAP complex has been clearly 
illustrated. TEAD-YAP complex triggers the expression of CTGF by binding to 
the TEAD motifs located in the promoter region of CTGF gene (Zhao et al, 
2008). Due to these two reasons, CTGF was selected as a model target gene for 
further analysis about how RUNX3 regulated TEAD-YAP complex’s function.  
 Two gastric cancer cell lines were used in this experiment, MKN28, which 
does not express any endogenous RUNX3, and HGC-27, in which endogenous 
RUNX3 is expressed at a high level. Exogenous RUNX3 would be introduced 
into MKN28 while endogenous RUNX3 would be knocked down in HGC-27, 
and the expression level of CTGF would be determined by real-time PCR. 
 According to the result obtained in MKN28 cell line, CTGF expression was 
induced by YAPS127A, which could be reversed by reintroducing wild-type 
RUNX3. This inhibitory effect became weaker if the Luecine
121
 of RUNX3 was 
mutated to Histidine, which abolished RUNX3’s interaction with TEAD 
proteins, indicating that RUNX3-TEAD interaction plays an important role in 
this process. However, deleting the PY motif, which would impair the RUNX3-
YAP interaction, did not make any difference to the inhibitory effect caused by 
RUNX3, indicating that RUNX3-YAP interaction does not contribute to 
RUNX3’s inhibition on CTGF expression (Fig 5.7A, B). 
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 According to the result produced in HGC-27 cell line, knocking down of 
RUNX3 increased the expression of CTGF, indicating that the endogenous 
RUNX3 has an inhibitory effect on CTGF expression. When YAPS127A was 
overexpressed, the expression of CTGF was further up-regulated. This additive 
effect indicated that RUNX3’s negative regulation on CTGF expression by 
RUNX3 is not dependent on YAP (Fig 5.7C, D). 
 Taken together, these results obtained from both gastric cancer cell lines 
pointed to one common conclusion that RUNX3 suppresses the expression of 
CTGF, and RUNX3-TEAD interaction plays an important role in this process. 
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Figure 5.7 CTGF is negatively regulated by RUNX3 in gastric cancer cell lines. 
(A) Real-time PCR analysis of CTGF expression in MKN28 after RUNX3 
overexpression in MKN28 cell line. MKN28 cell was transfected with pcDNA-
Flag-YAPS127A (1 µg/well in a 6-well plate), pcDNA-Flag-RUNX3 (1 µg/well), 
pcDNA-Flag-RUNX3L121H (1 µg/well), pcDNA-Flag-RUNX3ΔPY (1 µg/well) 
plasmids accordingly. RNA was extract using Trizol at 48 hours after 
transfection. cDNA was reverse-transcripted and real-time PCR was performed 
and the result was normalized to GAPDH. Triplication was performed for each 
sample. Mean and standard deviation was shown in the figure. (B) Western blot 
result showing protein expression in the MKN28 cells. (C) Real-time PCR 
analysis of CTGF expression after RUNX3 knocking down in HGC-27 cell line. 
HGC-27 cell was transfected with siRUNX3 (100 pmol/well in a 6-well plate), 
pcDNA-Flag-YAPS127A (1 µg/well) accordingly. RNA was extract using Trizol 
at 48 hours after transfection. cDNA was reverse-transcripted and real-time PCR 
was performed and the result was normalized to GAPDH. Triplication was 
performed for each sample. Mean and standard deviation was shown in the 
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figure. (D) Western blot result showing protein expression in HGC-27 cells used 
for real-time PCR analysis of CTGF expression after RUNX3 knocking down. 
 
5.8 RUNX3 suppresses the expression of CTGF by preventing TEAD1 from 
binding to the promoter of CTGF 
 From previous experiments, we had already known that RUNX3 could 
suppress the expression of CTGF. At the same time, the data from Chapter 4 
showed that RUNX3 impairs the DNA binding ability of TEAD proteins. Based 
on these observations, we hypothesized that RUNX3 might inhibit the 
expression of CTGF by preventing TEAD proteins from binding to the promoter 
of CTGF. To test this hypothesis, Chromatin IP was performed using antibody 
targeting TEAD1 in MKN28 cell, as described in Chapter 2.12 
 The result of chromatin IP showed that CTGF promoter was enriched by 
TEAD1 antibody in MKN28 cell line, and this enrichment was reduced when 
RUNX3 was overexpressed, indicating that RUNX3 down-regulates the 
expression of CTGF by directly inhibiting TEAD proteins from binding to the 
promoter of CTGF (Fig 5.8). 
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Figure 5.8 RUNX3 suppresses the expression of CTGF by preventing TEAD1 
from binding to the promoter of CTGF. MKN28 cells were transfected with 
pEGFP-C1-RUNX3 (5 µg/10cm dish). Cells were harvested at 48 hours after 
transfection and chromatin IP was performed using TEAD1 antibody or normal 
mouse IgG as described in Chapter 2.12. The precipitated DNA was analyzed 
using real-time PCR. The result showed that overexpression of RUNX3 could 
impair the enrichment of CTGF promoter by TEAD1 protein. 
 
5.9 RUNX3 overexpression significantly reduces growth of gastric cancer cell 
lines in soft agar 
 Gain of anchorage-independent growth is one of the key steps of malignant 
transformation. The soft agar colony formation assay is a common method to 
measures cell proliferation in an anchorage-independent manner. By analyzing 
the soft agar colony formation after RUNX3 overexpression in gastric cancer 
cell lines, the role which RUNX3 played in the malignant transformation of 
cancer cells could be evaluated. 
 MKN28 and AGS cell lines were used in this experiment since neither of 
them expresses endogenous RUNX3. Both cell lines were able to form hundreds 
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of colonies if they were infected with vehicle virus control, but their ability to 
grow in an anchorage-independent manner was remarkably impaired when 
RUNX3 was overexpressed. The mutation of Leucine
121
 of RUNX3 could 
partially neutralize the negative effect of RUNX3 on cell growth, indicating that 
RUNX3’s interaction with TEAD proteins played an important role for 
RUNX3’s ability to inhibit the anchorage-independent growth of gastric cancer 
cells (Fig 5.9A, B). 
 
Figure 5.9 RUNX3 overexpression significantly reduces the growth of gastric 
cancer cell lines in soft agar. (A) Soft agar colony formation assay after RUNX3 
overexpression in MKN28 and AGS cell lines. Cells were infected with 
retrovirus overexpressing GFP-RUNX3 and stable cell lines were selected using 
puromycin. Cells were seeded in soft agar and colonies were stained after 3 
weeks. (B) Quantification for the results of the soft agar colony formation assay 
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after RUNX3 overexpression in MKN28 and AGS cell lines. Triplication was 
made for each sample. Mean and standard deviation were shown. 
 
5.10 RUNX3 inhibits the overgrowth of gastric cancer cells caused by TEAD-
YAP complex 
 The results reported earlier by others showed that overexpression of 
TEAD4-YAP fusion protein should result in better cell survival in soft agar, 
since TEAD4-YAP fusion protein would trigger the expression of downstream 
genes promoting cell survival and proliferation (Zhao et al, 2008). Here, we 
wanted to test whether RUNX3 was able to prevent the enhancement of 
anchorage-independent cell growth caused by TEAD4-YAP fusion protein. This 
experiment was carried out in MKN28 cell line, in which endogenous RUNX3 
was not expressed. 
 The result showed that overexpression of TEAD4-YAP fusion protein led 
to the formation of more colonies growing in soft agar, compared with vehicle 
control. The growth of colonies was significantly reduced when RUNX3 was 
overexpressed, regardless of whether TEAD4-YAP fusion protein was 
expressed or not. However, when the Leucine
121
 of RUNX3 was mutated, the 
inhibitory effect of RUNX3 was lost (Fig 5.10A, B).  
 Taken together, these results indicated that RUNX3 inhibits the activity of 
TEAD4-YAP fusion protein and reduces the growth advantage caused by 
TEAD-YAP fusion protein. 
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Figure 5.10 RUNX3 inhibits the overgrowth of gastric cancer cells caused by 
TEAD-YAP complex. (A) Soft agar colony formation assay after the 
overexpression of TEAD4-YAP fusion protein and RUNX3 in MKN28 cell line. 
Cells were infected with retrovirus overexpressing TEAD4-YAP and GFP-
RUNX3 accordingly. Stable cell lines were selected using hygromycin and 
puromycin. Cells were seeded in soft agar and colonies were stained after 3 
weeks. (B) Quantification for the soft agar colony formation assay after the 
overexpression of TEAD4-YAP fusion protein and RUNX3 in MKN28 cell line. 
Triplication was made for each sample. Mean and standard deviation were 
shown. 
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5.11 RUNX3 and TEAD1 work in the same pathway to regulate the growth of 
gastric cancer cells 
 Both knocking down TEAD1 and ovrexpressing RUNX3 would cause the 
reduction of cell growth. Here we wanted to test the combined effects of both 
treatments to see whether TEAD1 and RUNX3 worked in the same pathway. If 
the effects of knocking down TEAD1 and overexpressing RUNX3 were additive, 
it meant that they worked in separate pathways. Otherwise, it meant that they 
worked in the same pathway. 
 According to the result of cell proliferation assay, both knocking down of 
TEAD1 and overexpression of RUNX3 would cause 40% reduction of cell 
growth in MKN28 gastric cancer cell line. However, the combined treatment did 
not cause a significant reduction any further, compared with single treatment. 
This result indicated that TEAD1 and RUNX3 work in the same pathway (Fig 
5.11A, B).  
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Figure 5.11 RUNX3 and TEAD1 work in the same pathway to regulate the 
growth of MKN28 cell. (A) Relative cell viability after knocking down TEAD1 
and overexpressing RUNX3 in MKN28. Stable cell lines expressing GFP-
RUNX3 or GFP-RUNX3L121H were transfected with siTEAD1 (100 pmol/well 
in a 6-well plate). The cells were seeded into 96-well plate and cell proliferation 
was monitored by WST-1 assay at 96 hours. Triplication was made for each 
sample. Mean and standard deviation were shown. (B) Western blot result 
showing protein expression after knocking down TEAD1 and overexpressing 
RUNX3 in MKN28. 
 
5.12 Overexpressing TEAD1 compensates for RUNX3’s negative effect on cell 
growth 
 From previous experiments, it was shown that TEAD1 and RUNX3 
function in the same pathway to regulate cell growth. Here we performed 
another cell growth analysis by overexpressing TEAD1 and RUNX3 together to 
test whether extra TEAD1 could compensate for the negative effect on cell 
growth caused by RUNX3’s suppression on TEAD-YAP activity.   
 The result of cell proliferation assay revealed that overexpressing TEAD1 
alone did not exhibit any significant influence on cell growth, but it could 
increase cell growth in the context of RUNX3 overexpression, compensating for 
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RUNX3’s negative effect on cell growth (Fig 5.12A, B). This result indicated 
that extra TEAD1 could partially rescue the negative effect on cell growth 
caused by RUNX3 overexpression, supporting our previous observations that 
RUNX3 reduces cell growth by suppressing the activity of TEAD proteins. 
 
Figure 5.12 Overexpressing TEAD1 compensates for RUNX3’s negative effect 
on cell growth. (A) Relative cell viability after overexpressing TEAD1 and 
RUNX3 in MKN28 cell. Cells were infected with retrovirous overexpressing 
HA-TEAD1 and GFP-RUNX3. Stable lines were selected using hygromycin 
and puromycin, and seeded into 96-well plates for proliferation assay using 
WST-1 method. Triplication was made for each sample. Mean and standard 
deviation were shown. (B) Western blot result showing protein expression after 
overexpressing TEAD1 and RUNX3 in MKN28 cell. 
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5.13 Summary and discussion 
 According to our analysis, TEAD-YAP complex is highly oncogenic for 
gastric epithelial cells, whose overexpression is important for the proliferation of 
gastric cancer cell lines (Fig 5.1, 5.2). Overexpression of YAP and TEAD 
proteins is frequently observed in gastric cancer specimens, ant it is significantly 
correlated with a shorter overall survival time for gastric cancer patients (Fig 5.3, 
5.4). The expression of RUNX3 is relatively lower in patients with high YAP-
TEAD expression, and RUNX3 suppresses the expression of 36.7% (69/187) 
candidate TEAD-YAP target genes in gastric cancer (Fig 5.5, 5.6). Further 
analysis on RUNX3’s regulation on CTGF, one TEAD-YAP target gene, 
revealed that RUNX3 suppresses the expression of CTGF by directly preventing 
TEAD proteins from binding to the promoter of CTGF (Fig 5.7, 5.8).  
 According to the soft agar colony formation assays performed using gastric 
cancer cell lines, RUNX3 reduces the anchorage-independent cell growth by 
inhibiting the activity of TEAD-YAP complex (Fig 5.9, 5.10). The result of cell 
proliferation assays also supported the conclusion that RUXN3 and TEAD 
proteins work in the same pathway to control the growth of gastric cancer cell 
lines, and overexpressing TEAD1 partially compensates for RUNX3’s negative 
effect on cell growth (Fig 5.11, 5.12). All these results suggested us a novel 
mechanism for understanding the role of RUNX3 as a tumour suppressor in 
gastric cancer. 
 It is interesting to find that knocking down TEAD1 and knocking down 
YAP did not lead to exactly the same response in gastric cancer cell lines (Fig 
5.2), which might be due to several reasons. First, different cells might have 
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different amount of four TEAD proteins. In some cells, TEAD1 might be the 
major form, while other TEAD proteins dominate in other cell lines. In the latter 
situation, knocking down TEAD1 alone might lead to a smaller effect due to the 
compensation by other TEAD proteins. Secondly, TEAD proteins might utilize 
co-activators other than YAP, for example, TAZ or SRC-1, in gastric cancer 
epithelial cells, which could explain why sometimes knocking down of YAP 
causes a milder effect for cell growth, compared with knocking down TEAD1. 
Thirdly, YAP is multi-functional. It is involved in proproliferative as well as 
pro-apoptotic pathways. Knocking down YAP might reduce the signal outputs 
for both sides, and the mixed effects could be neutralized and weaker. However, 
since both stable knocking down TEAD1/3/4 by shRNA and transient knocking 
down TEAD1 or YAP alone by esiRNA led to reduced growth in most gastric 
cancer cell lines, it seems that the major function of YAP is still promoting the 
survival of gastric cancer cells. 
  Even though TEAD1 is universally expressed at a high level in gastric 
cancer cell lines, YAP overexpression is only observed in a portion of gastric 
cancer cell lines (Fig 5.1B), Ironically, overexpression of YAP is much more 
severe and frequently observed in clinical samples than overexpression of 
TEAD1. This can probably be explained by the fact that YAP is always under 
strict posttranslational regulations by multiple pathways, causing its rapid 
degradation, and YAP is also able to increase the expression of its own, rapidly 
forming a positive feedback loop. So once YAP’s negative regulations are lost, 
YAP gets accumulated quickly. However, there is little evidence showing that 
TEAD proteins undergo such a stringent regulation. There is only one report 
about TEAD4’s overexpression due to loss of promoter methylation in gastric 
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cancer. According to their IHC data, TEAD4’s up-regulation is not as dramatic 
as YAP’s accumulation, just like what we observed here (Lim et al, 2014). 
 According to our analysis, the expression of both RUNX1 and RUNX3 is 
significantly reduced in gastric cancer patients with higher TEAD-YAP 
expression (Fig 5.5). This finding is very interesting, and difficult to explain, 
because micro array analysis can not offer any information about causal 
relationship. It is possible that reduction of RUNX1/3 expression causes hyper 
activation of TEAD-YAP complex and vice versa. We did not explore this 
question any further here since we already knew that RUNX3 was able to inhibit 
the activity of TEAD-YAP complex based on Chapter 4, but actually more work 
could be done to study whether there is a direct relationship between TEAD-
YAP and RUNX proteins at the transcriptional level. 
 To identify potential TEAD-YAP target genes which could be up-regulated 
by TEAD-YAP complex in gastric cancer, we compared micro array data 
generated in gastric cancer tissues with data generated in MCF10A cell line after 
YAP overexpression, looking for genes which could be up-regulated by YAP in 
MCF10 and showed significant correlation with TEAD-YAP’s overexpression 
in gastric cancer specimen (Fig 5.6A). This strategy is not perfect due to two 
reasons: first, MCF10A is a mammary epithelial cell lines, which might have 
different YAP-TEAD target genes with gastric epithelial cells due to the 
difference of cell context; Secondly, significant correlation does not guarantee 
the existence of a direct regulation of one gene on another, which might be 
biased by the third factor which is correlated with the expression of these two 
genes at the same time. However, we still used this strategy due to the lack of 
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alternative choices. Other experiments like ChIP-Seq need to be performed if we 
want to confirm whether these genes are direct targets of TEAD-YAP complex. 
However, our major purpose here is to identify a gene expression pattern 
correlated with enhanced TEAD-YAP activity, so the current strategy is already 
enough to achieve this goal. 
 After that, these candidate TEAD-YAP target genes was compared with 
micro array data generated in SNU16 gastric cancer cell lines in which RUNX3 
was knocked down by shRNA, and 36.7% of these genes were up-regulated 
after RUNX3 knocking down, indicating that a considerate portion of potential 
target genes are suppressed by RUNX3 in SNU16 cell (Fig 5.6B). However, for 
most of these genes, the down-regulation was not very dramatic, which might be 
due to three reasons: first, these target genes might not be fully activated in 
SNU16 due to cell context or impropriate cell density; secondly, the regulation 
of RUNX3 on TEAD-YAP target genes might not be the major way of 
regulation; thirdly, the regulation of RUNX3 on TEAD-YAP target genes might 
be selective, which means that the strong regulatory effect would be limited to a 
small number of genes due to promoter context. Based on the available 
information, it is difficult to judge which hypothesis is right, but at least we are 
sure that RUNX3 has a negative effect on a considerate portion of candidate 
TEAD-YAP target genes in gastric cancer. 
 Real time PCR and Chromatin IP experiments were performed to show that 
RUNX3 could suppress CTGF expression by preventing TEAD1 from binding 
to CTGF promoter (Fig 5.7, 5.8). CTGF was chosen here as an model gene due 
to three reasons: first, CTGF is the best characterized TEAD-YAP target genes, 
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whose TEAD binding site in promoter is already known (Zhao et al, 2008); 
Secondly, CTGF is one of the most significant up-regulated candidate TEAD-
YAP target genes after RUNX3 knocking down; Thirdly, clinical studies have 
shown that overexpression of CTGF is significantly correlated with lymph node 
metastasis and poor prognosis in patients with gastric cancer (Liu et al, 2007; 
Liu et al, 2008). Knocking down of endogenous CTGF expression inhibits the 
growth and invasion of gastric cancer cells in vitro and attenuates peritoneal 
dissemination in vivo (Jiang et al, 2011). 
 More TEAD-YAP target genes should be tested to confirm whether our 
hypothesis is applicable to a broader field, which would require more 
optimization due to the lack of detailed background knowledge about how these 
genes are regulated by TEAD-YAP complex. In the clustering figure 
summarizing all the candidate TEAD-YAP target genes which could be 
suppressed by RUNX3 (Fig 5.6B), many genes attracted our attention due to 
their strong correlation with poor prognosis of gastric cancer or other kinds of 
cancer, for example, FGF2 (Fibroblast growth factor 2), AXL (AXL Receptor 
Tyrosine Kinase) and FGFR1 (Fibroblast growth factor receptor 1) (Andre et al, 
2013; Katoh & Katoh, 2006; Wu et al, 2002). 
 In this chapter, both soft agar colony formation assays as well as regular 
cell proliferation assays were performed to evaluate cell growth. These two 
assays reflect two different kinds of cell growth. Regular cell proliferation assay 
reflects cell growth on traditional culture dish, which is a two dimensional 
process, while soft agar colony formation reflects cell growth in soft agar, which 
is a three dimensional process. Actually soft agar colony formation assay 
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includes two stages of cell growth. First, the cells need to overcome apoptosis 
caused by loss of anchorage to initiate the first few rounds of division. Then the 
cells would proliferate faster after they have set up a minimal population 
offering cell-cell contact signals in favour of survival and proliferation. The 
former stage is actually the opposite process of Anoikis, a form of programmed 
cell death which is induced by anchorage-dependent cells detaching from the 
surrounding extracellular matrix (ECM). 
 Overexpressing TEAD-YAP fusion protein in MKN28 cell increased the 
number of visible colonies formed in soft agar, indicating that TEAD-YAP 
complex could prevent the cell from Anoikis (Fig 5.10). However, in MKN28 
and AGS cells, restoring wild-type RUNX3 expression by retrovirus infection 
could significantly reduce the number of visible colonies while restoring 
RUNX3L121H mutant lacking TEAD binding ability generated a much weaker 
inhibitory effect on the growth of colonies, indicating that TEAD-YAP complex 
is protecting the cell from Anoikis while RUNX3 promotes Anoikis by 
inhibiting TEAD-YAP complex. The inhibitory effect caused by RUNX3 in 
regular two dimensional culture dishes is weaker than RUNX3’s effect in soft 
agar assay, indicating that RUNX3 plays important roles in both processes: 
Anoikis and inhibition of cell proliferation, and at least a part of these effects are 
achieved by interfering with the functions of TEAD-YAP complex.  
 For a better understanding of RUNX3’s role in the regulation of TEAD-
YAP complex, in vivo work should be performed to examine whether TEAD-
YAP activity shows any difference when RUNX3 is knocked out in mice. 
However, this work can not be done due to the time limit of PhD candidate. The 
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internal rescue effects among all three RUNX proteins also add difficulties for 
the design of experiments. Currently, it has already been reported that knocking 
out Runx3 would lead to neoplasia in lung epithelial cells, gastric epithelial cells 
and small intestinal epithelial cells in mice (Chen, 2012; Lee et al, 2010; Li et al, 
2002). At the time of these publications, RUNX3’s connection with TEAD-YAP 
complex was not discovered yet, so there was no information about Hippo 
pathway’s status in these Runx3 knockout mice. One quick option is to measure 
the Hippo pathway signature by micro array in the neoplasia tissues obtained 
from Runx3 knockout mice, and to compare it with the signature in normal 
epithelial cells in these tissues.  
  Taken together, based on our current findings from the analysis of gastric 
cancer specimens as well as experiments performed in gastric cancer cell lines, 
we can conclude that RUNX3 functions as a tumour suppressor in gastric cancer 
partially by suppressing the activity of oncogenic TEAD-YAP complex.  
  





Chapter 6  
General discussion 
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6.1 Summary of findings 
 This research project was designed to examine the protein-protein 
interaction between RUNX3 and TEAD proteins. The project could be divided 
into three parts. The first part studied how these proteins interacted with each 
other. The second part focused on how RUNX3-TEAD interaction influenced 
the transcriptional function of TEAD proteins. The third part studied the 
biological significance of this interaction in gastric cancer. 
 In the initial part of this project (Chapter 3), we showed that RUNX3 and 
TEAD1 could coexist in the same complex in HGC-27 cell line by endogenous 
IP experiment (Fig 3.1). Then I excluded the possibility that TEAD and RUNX3 
interacted through YAP by performing exogenous IP using a RUNX3 mutant 
which lacked YAP binding ability (Fig 3.2). After confirming the direct protein-
protein interaction between RUNX3 and TEAD proteins, I mapped the domains 
which both proteins required to interact with each other using multiple 
techniques, including exogenous IP using truncated constructs in HEK293T and 
GST pull down using purified proteins (Fig 3.3-3.6). According to the results, 
Runt domain of RUNX3 was utilized for its interaction with TEAD4, while the 
residues 101-125 of TEAD4 were crucial for its interaction with RUNX3. These 
25 amino acid residues include a large part of Helix three (Residues 97-109) of 
TEAD4, which is the DNA recognition helix. The result of sequential IP 
experiment supported our hypothesis that TEAD4, YAP and RUNX3 could 
form a ternary complex, which indicated that RUNX3 is able to interact with 
both transcriptionally active or inactive forms of TEAD proteins (Fig 3.7-3.8).  
In the last part of this chapter, we screened several RUNX3 mutants with point 
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mutations within Runt domain, and discovered that a point mutation at 
Leucine
121
 of RUNX3 could totally abolish its binding with TEAD proteins, 
while retaining most of RUNX3’s other functions, so the RUNX3L121H mutant 
would be widely used in the next two chapters to study the biological functions 
of RUNX3-TEAD interaction (Fig 3.9-3.10). 
 In the second part of this project (Chapter 4), we aimed to figure out how 
RUNX3-TEAD interaction affected the function of TEAD proteins. First, the 
luciferase reporter assay showed that RUNX3 reduced the transcriptional 
activity of TEAD proteins (Fig 4.1). However, the RUNX3-TEAD interaction 
did not have any obvious influence on the binding between TEAD and YAP 
(Fig 4.2). So we examined whether RUNX3 could reduce the DNA binding 
ability of TEAD proteins by both EMSA assay and transcription factor 
enrichment assay. RUNX3 was found to significantly reduce the DNA binding 
ability of TEAD proteins, causing the reduction of TEADs’ transcriptional 
activity (Fig 4.3 - 4.4). 
 In the last part of this project (Chapter 5), we examined the biological 
significance of RUNX3-TEAD interaction in gastric cancer. First we proved that 
TEAD-YAP complex was oncogenic in gastric cancer cell lines (Fig 5.1, 5.2), 
and its overexpression was significantly correlated with poor prognosis in 
patients with gastric cancer (Fig 5.3, 5.4). We used bioinformatic approach to 
identify a group of candidate targets genes which got up-regulated by TEAD-
YAP complex in gastric cancer specimen. Then we compared this group of 
genes with the micro array result generated in SNU16 gastric cancer cell lines in 
which RUNX3 was knocked down, and found that a considerable portion 
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(36.7%) of candidate TEAD-YAP target genes were suppressed by RUNX3 in 
SNU16 cell, indicating that RUNX3 played an important role to suppress the 
activity of TEAD-YAP complex in gastric cancer (Fig 5.6). We also validated 
RUNX3’s inhibitory effect on CTGF by real-time PCR and Chromatin IP to 
show that RUNX3 could inhibit CTGF’s expression by preventing TEAD 
proteins from binding to CTGF’s promoter (Fig 5.7, 5.8). Then we performed 
both cell proliferation assays as well as soft agar colony formation assays to 
show that RUNX3 could significantly reduce the cell growth of gastric cancer 
cell lines partially through suppressing the activity of TEAD-YAP complex (Fig 
5.9-5.12). 
 Taken together, we discovered that RUNX3 forms direct protein-protein 
interaction with TEAD proteins, and down-regulates the transcriptional activity 
of TEAD-YAP complex by preventing TEAD proteins from binding to DNA. 
RUNX3 suppresses the expression of a considerate portion of TEAD-YAP 
target genes in gastric epithelial cells and this could partially explain how 
RUNX3 suppresses the growth of gastric cancer cells and functions as a tumour 
suppressor. 
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6.2 Significance of findings 
 The present work is an attempt to thoroughly examine the protein-protein 
interaction between RUNX3 and TEAD proteins. This study suggested that 
RUNX3 could significantly inhibit the transcriptional activity of TEAD proteins 
by direct protein-protein interaction and the loss of RUNX3 in gastric cancer 
would lead to a more aggressive progression of disease due the enhanced TEAD 
activity. 
 Our finding pointed out RUNX3’s novel role as a negative regulator of 
TEAD-YAP complex within cell nucleus, adding a new facet for a better 
understanding about the mechanisms how RUNX3 functions as a tumour 
suppressor. 
 Recently, great progression has been achieved for the mechanism study 
about how RUNX3 functions as a tumour suppressor. Our understanding about 
the functions of this critical protein has reached a new level.  
 Based on published literature as well as the research conducted in our group, 
loss of RUNX3, which is commonly observed in various kinds of solid tumours, 
would lead to severe changes for the biology of cells, paving the way for 
oncogenic transformation (Li et al, 2002). These changes include reduced 
expression of key proteins for cell homeostasis (Chi et al, 2005; Yano et al, 
2006), enhanced Wnt signalling (Ito et al, 2008), stronger EMT tendency (Voon 
et al, 2012), failure to initiate cell defence against oncogenic K-Ras (Lee et al, 
2013), trembling genome stability due to incomplete repair of DNA damage, 
and elevated TEAD-YAP activity (Fig 6.1). These changes cover major steps 
for oncogenic transformation, which can explain why RUNX3 is such a hotspot 
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for promoter hypermethylation as well as LOH (Loss of heterozygosity) in solid 
tumours (Carvalho et al, 2005; Fan et al, 2011). 
 The grave consequences caused by loss of RUNX3 suggest us the potential 
applications of RUNX3 for the treatment of cancer. There are two possible ways 
to reach this goal: first, restoring the RUNX3 expression in cancer cells, which 
can be achieved by gene therapy or small molecular compounds which can 
reverse the hyper-methylation on RUNX3’s promoter; secondly, developing 
short peptides which mimic the critical part of RUNX3 proteins, for example, 
the sequence which interact with TEAD proteins or β-catenin/TCF4. Currently, 
several drugs which can reverse promoter methylation, including azacytidine, 
decitabine, and fazarabine, are already used as drugs against cancer. More 
research should be conducted to examine these drugs’ effect on RUNX3’s 
restoration. 
 Recently, peptides as well as small molecular compounds disrupting the 
TEAD-YAP complex have already been available, and they both shown 
dramatic antagonizing effect on TEAD-YAP activity in animal models (Jiao et 
al, 2014; Liu-Chittenden et al, 2012a). According to our findings, loss of 
RUNX3 would increase the risks of hyper-activated TEAD-YAP complex, 
which can be used as one of the criterions to decide whether anti-TEAD-YAP 
therapy should be used for the benefits of patients at the age of personalized 
medicine.  
- 142 - 
 
 
Figure 6.1 A summary of major changes caused by loss of RUNX3 in epithelial 
cells. 
 
6.3 Future works 
 Our current understanding about the interaction between RUNX3 and 
TEAD proteins is still incomplete. There are several questions to answer. 
 First, the detailed structure of RUNX3-TEAD complex remains unknown. 
Several methods can be used to determine the structure of a protein, including 
X-ray crystallography, NMR spectroscopy, and electron microscopy 
(Schneidman-Duhovny et al, 2012). Collaborative work is required to fulfill 
such tasks. Once the structure is solved, new windows would be opened for 
designing small molecular compounds or short peptides mimicking RUNX3’s 
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binding with TEAD proteins to prevent TEAD proteins from binding to DNA 
(Takeda-Shitaka et al, 2004). 
 Secondly, more TEAD-YAP target genes under the negative control of 
RUNX3 should be identified. In Chapter 5.6, we already generated a list of 
candidate TEAD-YAP target genes which were negatively regulated by RUNX3 
in SNU16 gastric cancer cell line. However, our results were merely based on 
the analysis of micro array data. A more comprehensive study should be 
conducted using ChIP-Seq technique, which measures protein-genome 
interaction at a global level (Park, 2009). By comparing the DNA binding 
pattern of TEAD proteins before and after RUNX3 overexpression, all the genes 
which follow the regulation model which we proposed in this thesis can be 
identified. 
 Thirdly, our model should be tested in more models other than gastric 
cancer. It is already known that TEAD-YAP plays an oncogenic role in various 
kinds of solid tumours, and RUNX3 is also expressed in other tissues like skin 
and brain (Inoue et al, 2002; Lee et al, 2011b). It is highly possible that our 
model can be applied in a broader field. 
 Last but not least, more in vivo work should be done to study the 
significance of RUNX3 for the regulation of TEAD-YAP complex. There are 
many ways to achieve TEAD-YAP hyper-activation in mouse model, including 
knocking out Hippo pathway component Sav1 or Merlin, or knocking in 
constitutive activated YAPS127A mutant (Cai et al, 2010; Jiao et al, 2014). It 
would be interesting to examine whether knocking out of RUNX proteins would 
cause a more severe phenotype for hyper-activated TEAD-YAP complex.  
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 In general, the data presented in this thesis demonstrate that RUNX3 is a 
novel negative regulator for TEAD proteins, adding to our knowledge about 
how RUNX3 functions as a tumour suppressor in gastric cancer. However, more 
thorough investigations are still required for a comprehensive understanding of 
RUNX3-TEAD interaction. 
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